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Antibodies or immunoglobulins are large proteins, which are part of the adaptive immune 
response in vertebrates. They were first described by van Behring and Kitasato who postulated 
the existence of blood agents neutralising diphtheria toxin, thus enabling the first successful 
therapy of this disease (von Behring and Kitasato 1890). Following decades of research 
revealed their structure and their essential role in the immune system. Biochemically, 
antibodies can be divided into five different isotypes – the monomeric IgA, IgD and IgG and 
the multimeric IgA (dimer) and IgM (pentamer). Herein, IgG is the most predominant isotype 
with the longest serum half-life (Schroeder and Cavacini 2010). Immunoglobulins are 
composed of two heavy (H) and two light chains (L) connected by disulfide bonds (Figure 1). 
Each chain consists of N-terminal variable (V) and C-terminal constant (C) domains. In case 
of IgG, the H-chain has a molecular weight of ~50 kDa and comprises one variable (VH) and 
three constant domains (CH). The hinge region between CH1 and CH2 harbours conserved 
cysteine residues facilitating disulfide bonding between the two H-chains. The L-chain only 
consists of one V- and C-domain (VL & CL) and has a molecular weight of ~25 kDa. Each L-
chain is linked to one H-chain by disulfide bonds between CH1 and CL (Schroeder and 
Cavacini 2010). The constant domains CH2 and CH3 together form the Fc fragment (fragment 
crystallisable), which mediates effector functions through interaction with specific Fcγ-
receptors expressed on several immune cells (Nimmerjahn and Ravetch 2008). The V-
domains (VH & VL) in turn are summarised as the Fv fragment (fragment variable) and are 
essential for antigen binding. Each V-domain comprises three complementary determining 
regions (CDR) flanked by framework sequences (FRs). The hypervariable CDRs mainly 
determine the specificity of the antibody and form the paratope, which is a specific binding site 
for the epitope on the respective antigen. According to the lock-and-key-principle binding 
between paratope and epitope is highly specific. Hence, antibodies can distinguish between 
closely related antigens if they do not express the same epitope but also bind to different 
antigens if they share the same or a similar epitope, which is termed cross-reactivity 
(Schroeder and Cavacini 2010).  
The vast diversity of the natural B cell repertoire is created by genetic recombination early in 
the development of the progenitor B cell. The V-domains are composed of different gene 
segments termed “variable” (V), “diversity” (D) and “joining” (J), which are assembled to the 
VH (VDJ-recombination) and the VL (VJ-recombination) (Tonegawa 1983). For the L-chain 
there are two sets of gene segments located on different chromosomes, thus resulting in the 
κ and λ light chain subtypes. Allelic exclusion herein ensures, that each B cell expresses 
antibodies of only one specificity (Rajewsky 1996). Initially, antibodies are expressed as 
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surface immunoglobulins as part of the B cell receptor on naïve B cells (IgM and IgD). Upon 
activation, B cells undergo class switch recombination (CSR) and somatic hypermutation 
(SHM) to shape antibody affinity and facilitate secretion of soluble antibodies (Rajewsky 1996). 
These can directly neutralise or block toxins or pathogens (Fühner et al. 2018) or activate 
effector cells by their Fc part leading to phagocytosis (Aderem and Underhill 1999) or cell lysis 
and apoptosis through perforins and granzymes secreted by NK cells (Seidel et al. 2013). 
Furthermore, through the interaction with C1q antibodies can activate the complement 
cascade mediating cell lysis (Ricklin et al. 2010). 
 
 
Figure 1: Antibody formats. A: Full-length IgG1. B: Fab fragment. C: scFv fragment with flexible 
peptide linker.  
 
Apart from their natural function, antibodies find broad application in molecular biology, 
diagnostic and therapy. The production of monoclonal antibodies was revolutionised by the 
introduction of the hybridoma technology by Köhler and Milstein in 1975 (Köhler and Milstein 
1975). Whereas previously antibodies were obtained from polyclonal sera of immunised 
animals, this technology was based on the fusion of antibody-producing B cells with immortal 
myeloma cells enabling infinite antibody production. In further investigations, antibodies were 
amplified from hybridoma clones and subcloned for recombinant production in different cellular 
systems (Jäger et al. 2013; Horwitz et al. 1988). Skerra and Plückthun firstly demonstrated the 
production of the Fv in bacteria (Skerra and Plückthun 1988), which was further improved by 
the introduction of a flexible peptide linker connecting VH and VL (Huston et al. 1988). The 




facilitating antigen-binding. Due to its solubility and its easy and profitable production in 
bacterial systems, the scFv is widely used in different applications (Ahmad et al. 2012).  
1.2 Phage display 
The development of recombinant antibodies from hybridoma cells revolutionised antibody 
technology but still required immunisation of donor animals, thus involving a limitation for 
certain toxins. Furthermore, the isolated antibodies, which were mainly derived from mice were 
found to be immunogenic in humans, which complicated their clinical application (Schroff et al. 
1985). Introduction of the phage display technology in the early 1990s enabled the in vitro 
isolation of monoclonal antibodies from fully human antibody libraries and was a breakthrough 
for modern antibody discovery (McCafferty et al. 1990; Barbas et al. 1991; Breitling et al. 1991). 
For generation of antibody libraries, V-genes are amplified directly from B cells obtained from 
human blood and subcloned into a special plasmid containing a phage packaging signal 
(phagemid). The phagemid system uncouples the phage production and thus facilitates 
improved antibody production and gene library amplification (Breitling et al. 1991). Within the 
phagemid, the resulting scFv fragments are fused to the gene gIII of the viral minor coating 
protein pIII of the filamentous phage M13K07 and cloned into E. coli. Thus, the scFv-pIII fusion 
is integrated during phage assembly resulting in phage particles, which both present the 
antibody on their surface and also contain its genetic information. Once the gene libraries are 
converted to phage libraries (“packaging”), specific antibodies can be selected in a process 
termed panning (Hust et al. 2014; Russo et al. 2018) (Figure 2). Antibody-phage are incubated 
on a desired antigen, which is immobilised on a defined surface. Whereas unbound phage are 
washed away, bound phage are eluted and amplified upon re-infection. This way, antigen-
binding phage are enriched over typically three panning rounds. Thanks to the coupling of 
antibody phenotype and genotype within the phage, the selected antibodies can be easily 
produced in E. coli, screened and identified. This way, phage display facilitates the selection 
of fully human antibodies against any type of antigen under adjustable panning conditions.  
Following the remarkable example of phage display, other display technologies have been 
developed including yeast (Boder et al. 2012) and mammalian cells (Bruun et al. 2017). 
Whereas in phage display, library sizes of 1010 can be easily covered, alternative technologies 
suffer from low transformation efficacies, which results in diversities of typically 108 failing to 
represent the enormous diversity of many libraries. Depending on the application there are 
different library types divided into naïve, immune and synthetic libraries (Hust et al. 2014). For 
naïve and immune libraries, antibody genes are amplified form B cells isolated from human 
blood as described above. For naïve libraries, non-immunised healthy donors are used, from 
which the IgM genes are amplified. Thus, the naïve B cell repertoire is accessed resulting in 
large libraries (109 to 1010), which are particularly useful for universal antibody selection (Kügler 
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et al. 2015). Other universal libraries are synthetic libraries, which do not reflect a naturally 
accessible repertoire but are based on a defined framework, which is combined with random 
CDR sequences. These can be either mutated variants of natural CDRs (semi-synthetic) 
(Desiderio et al. 2001) or completely synthesised (fully synthetic) (Tiller et al. 2013). Immune 
libraries in contrast are based on the IgG repertoire of immunised donors such as vaccinated 
patients (Sadreddini et al. 2015), immunised animals (Miethe et al. 2014) or patients suffering 
from a certain disease such as HIV (Trott et al. 2014). Hence, in contrast to universal libraries, 
immune libraries need to be constructed de novo for each particular antigen. Due to the natural 
immune response, the resulting libraries are smaller (106 to 108) and biased towards the certain 








1.3 Tumor-infiltrating lymphocytes and the tumor microenvironment 
Referring to the observations of the world health organisation (WHO), cancer is still the leading 
cause of death worldwide accounting for the most or second most deaths before the age of 70 
in 91 out of 172 countries (Bray et al. 2018). In order to facilitate successful tumor growth, 
cancer cells need to evolve specific capabilities, which have been comprehensively 
summarised by Hanahan and Weinberg as the major hallmarks of cancer (Hanahan and 
Weinberg 2011). According to these hallmarks, tumor cells need to ensure continuous 
proliferation, resistance to growth suppressors and cell death signals, immortalisation, 
regulation of angiogenesis and finally, the activation of invasion and metastasis formation. 
Tumors are complex tissues comprising various different cell subsets such as stromal cells, 
blood vessel endothelial cells and immune cells, which interact both with each other as well as 
the tumor cells, thus forming a complex network summarised as tumor microenvironment 
(TME) (Alsibai and Meseure 2018). In order to facilitate optimal tumor growth, cancer cells 
regulate their TME to accomplish tumor-beneficial conditions. Notably, stromal cells such as 
tumor-associated fibroblasts, adipocytes and mesenchymal stem cells massively contribute to 
tumor progression (Hanahan and Coussens 2012). They promote tumor growth, activate 
angiogenesis, suppress anti-tumor immunity and facilitate invasion through the secretion of 
various growth factors and cytokines such as IL-10 and VEGF and by modulating the 
extracellular matrix (ECM) (Alsibai and Meseure 2018; Hanahan and Coussens 2012). The 
TME additionally comprises lymphoid-derived cells such as T cells, B cells and plasmacytoid 
dendritic cells (pCD) as well as myeloid-derived cells like tumor-associated macrophages 
(TAM), conventional DCs, neutrophils, mast cells and platelets (Alsibai and Meseure 2018). 
Contrasting to the initial assumption, that all immune cells within the TME contribute to tumor 
suppression, controversial findings have been reported for the different subsets. Thus, TAMs 
of the immunosuppressive phenotype M2 and myeloid-derived suppressor cells (MDSC) 
secrete IL-10 and other cytokines to inhibit cytotoxic T cells (CTL), B cells and NK cells in the 
TME (Murdoch et al. 2008). Additionally, they induce the development of regulatory T cells 
(Treg), which themselves inhibit other immune cells (Ghiringhelli et al. 2005). Furthermore, 
they promote expression of the M2 phenotype in other macrophages through an upregulated 
expression of NFκB, thus retaining and spreading immunosuppression (Hagemann et al. 
2008). Infiltration of tumors with CTLs and B cells in contrast, has been widely reported to 
correlate with improved prognosis and overall survival in different types of cancer (D.-Q. Zeng 
et al. 2016; Nazemalhosseini-Mojarad et al. 2019) strongly indicating, that these cells act anti-
tumorigenic. Whereas TAMs and MDSCs are randomly spread within the tumor stroma, tumor-
infiltrating lymphocytes (TIL) have been found to often form well-organised tertiary lymphoid 
structures (TLS) (Dieu-Nosjean et al. 2008; Germain et al. 2014). Majorly located at the 
invasive margin of the tumor, TLS show high similarity to conventional secondary lymphoid 
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organs (SLO) (Germain et al. 2015). They are composed of a B cell follicle, in which B cells 
are densely packed with follicular DCs and macrophages, a distinct T cell zone containing 
T cells accompanied by mature DCs and specialised high endothelial venules (HEV), which 
enable further immune cell infiltration from blood into the tissue (Colbeck et al. 2017; Germain 
et al. 2015). Surrounded by a ring of naïve B cells, a germinal center (GC) is formed, in which 
B cells expand and undergo class-switch recombination (CSR) and somatic hypermutation 
(SHM) (Germain et al. 2014). The T cells in turn are primed by DCs, which present tumor-
associated antigens within their MHC class I and II molecules. CD4+ T helper cells in turn 
stimulate proliferation and survival of germinal center B cells (Gatto and Brink 2010). Formation 
of TLS has been observed in various diseases harbouring chronic inflammation such as in 
graft rejection, autoimmune disorders, infectious diseases and also in cancer (Koenig and 
Thaunat 2016; Humby et al. 2009; Houtkamp et al. 2001; Dieu-Nosjean et al. 2008). In contrast 
to the preceding cases, in which TLS usually reflect high activity of disease, occurrence and 
abundance of cancer-related TLS have been reported to correlate with prolonged survival and 
improved prognosis (Goc et al. 2013; Germain et al. 2014; Sautès-Fridman et al. 2016). These 
findings provide evidence, that TLS contribute to an anti-tumor immune response harbouring 
tumor-specific cytotoxic T cells (CTL) and antibody-secreting B cells thus representing a local 
immune machinery, which complements the conventional immune response initiated by APCs 
migrating to SLOs (Germain et al. 2014). Considering the pivotal impact of immune cells on 
cancer development, Pagès and co-workers suggested to quantify cytotoxic (CD8+) and 
memory (CD45RO+) T cells within the tumor core and the invasive margin to calculate an 
immunoscore, which correlated with the survival of colorectal cancer patients (Pagès et al. 
2009). Although classification of cancer severity based on the universal TNM staging referring 
to the primary tumor burden (T) and the extension to draining lymph nodes (N) and metastases 
(M) established by the American Joint Committee on Cancer (AJCC) is widely accepted and 
provides information about tumor progression, this system fails to consider the immune 
microenvironment and its impact on prognosis. A recent comprehensive investigation 
comprising more than 2000 colon cancer patients indeed demonstrated the reliable prognostic 
value of the this novel system (Pagès et al. 2018). The immunoscore represents a promising 
complementation of the classical tumor staging model facilitating an improved prognostic 
estimation and outlines the great potential of the immune infiltrate for the development of novel 
diagnostic tools.  
1.4 Immune surveillance and immune escape 
Regarding the largely reported beneficial effects of some TILs, the prognostic impact of an 
immunoscore correlating with improved survival and the frequent occurrence of TLS in the 
tumor microenvironment, the question rises why tumors still develop, progress and even 




it has been suggested that the tumor is under immune control for an undefined period of time 
but manages to evade. This process is referred to as “immunoediting” and comprises three 
different states tumor-immune-interaction (Dunn et al. 2004). First, upon starting tumor 
development, an immune response is initiated keeping tumor growth under control. This 
process is termed immunosurveillance and has been initially described already 50 years ago 
by Burnet and Thomas (Burnet 1970). Within this state, neoepitopes on tumor cells are 
effectively recognised, immune cells are recruited to the tumor nest and TLS formation is 
induced to further drive an anti-tumor response (Dunn et al. 2004; Swann and Smyth 2007). 
Evidence for this theory has been provided by many studies reporting spontaneous tumor 
development in transplanted organs (Penn 1978), occurrence of paraneoplastic autoimmune 
syndromes (Graus et al. 1997) and an increased risk of tumorigenesis in immunosuppressed 
or immunodeficient patients (Gatti and Good 1971). Consistent with these findings it has been 
described, that the initial TME in lower staged tumors is mainly characterised by a high number 
of CTLs and pro-inflammatory macrophages (M1) as well as by high levels of IL-12 and INFγ 
(Fridman et al. 2014). However, if elimination of tumor cells is incomplete an equilibrium state 
is reached (Dunn et al. 2004), in which the cancer cells continue to undergo mutational cycles 
to overcome the immunogenic pressure for instance by losing or modifying their antigens or 
by downregulating their MHC complexes (Ferrone and Marincola 1995). Furthermore, as 
discussed before cancer cells interact with their TME to gain supportive cytokines and growth 
factors, to expand tumor vascularisation for an improved nutrient and oxygen supply and to 
promote an immunosuppressive environment. If these processes prevail and the immune 
system continues to fail in complete remission, immune-resistant and thus more aggressive 
tumor cells are selected over time finally evading the immune system (Swann and Smyth 
2007). This last state is termed immune escape and is marked by tolerated tumor progression, 
further modulation of the TME and induction of metastasis formation. Consistently, the immune 
microenvironment in later tumor stages is altered and characterised by predominance of Tregs 
and immunosuppressive M2 macrophages as well as by low levels of IFNγ and increased 
levels of IL-6 and VEGF (Chimal-Ramírez et al. 2013; Fridman et al. 2014).   
Immunoediting provides an explanation for the failing tumor regression in the presence of 
specialised immune cells. It is not surprising that this knowledge substantially drove the 
development of novel related therapeutic strategies. Various approaches have been described 
aiming to redirect the existing immune response and to invert immunoediting back to the state 
of immunosurveillance or even complete remission. To accomplish this, two major strategies 
have been described addressing the re-activation of exhausted or silenced immune cells on 
one hand and the enhancement of existing immune responses on the other (Velcheti and 
Schalper 2016). The first strategy majorly focusses on the blockade of immune checkpoints. 
These negative regulatory pathways exist in all immune cells to prevent tissue damage and 
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autoimmune reactions upon inflammations (Pardoll 2012). Ligand binding to surface 
checkpoint receptors such as CTLA-4, PD-1, TIGT or TIM-3, which are majorly expressed on 
T cells leads to their inactivation, thus mediating immunosuppression (Carter et al. 2002; Keir 
et al. 2005; Walunas et al. 1994; Yu et al. 2009; Zhu et al. 2005). Consequently, cancer cells 
upregulate expression of the respective ligands such as PD-L1 in order to promote inactivation 
of TILs, thus contributing to immune evasion (Blank et al. 2005; Hino et al. 2010; Mu et al. 
2011). Indeed, therapeutic antibodies targeting CTLA-4 and PD-1 such as ipilimumab and 
nivolumab already have been FDA-approved and showed promising results in clinical trials 
(Garon et al. 2015; Larkin et al. 2015; Reck et al. 2016). However, low response rates 
represented considerable drawbacks. This could be explained by preceding immunoediting, 
the concomitant highly immunosuppressive TME and the reduced immunogenicity of the 
tumor, which massively affect successful treatment. The second therapeutic strategy aims to 
facilitate an enhanced immune response including the application of cancer vaccines, 
cytokines such as interferons and interleukins or the adoptive T cell therapy (Velcheti and 
Schalper 2016). The latter describes the isolation of autologous cytotoxic T cells from tumor 
tissue or blood, which are expanded and stimulated in vitro and re-administered to the patients 
(Ho et al. 2003). To improve affinity and to overcome limitation to MHC-dependent target 
recognition, T cells were further equipped with chimeric antigen receptors (CARs) composed 
of immunoglobulin fragments (Barrett et al. 2014). The resulting CAR-T cells indeed showed 
improved performance but again success was limited by the high plasticity of tumor cells and 
the immunosuppressive TME (Velcheti and Schalper 2016). In summary various therapeutic 
approaches targeting tumor-immunity are currently under investigation and many of them show 
promising results in clinical trials (Marin-Acevedo et al. 2018). Nevertheless, breakthrough 
success is crucially limited by the substantial plasticity of cancer cells, the pivotal impact of the 
immunosuppressive TME and the accessibility of cancer-specific targets outlining the 
importance to further investigate the complex network of tumor-infiltrating lymphocytes for 
future cancer therapy.  
1.5 Tumor-infiltrating B lymphocytes and their controversial role in cancer 
As described before, B cells account for a considerable amount of the TME and were shown 
to infiltrate most human cancers. However, the role of the tumor-infiltrating B cells (TIL-B) in 
anti-tumor immunity is highly controversial. Whereas a number of studies describes, that high 
frequencies of TIL-Bs correlate with tumor progression and worse prognosis, a contrasting 
beneficial function of TIL-Bs has been reported in various cases (Largeot et al. 2019; Yuen et 
al. 2016). Most notably it has to be considered, that many of these studies are difficult to 
compare as results may vary within different types of cancer and due to the highly complex 
composition of the TME as described before. As consequence, B cells may differ in their 




their surrounding interaction partners, thus resulting in different effects in anti-tumor immunity. 
Herein the special subpopulation of regulatory B cells (Breg) gained attention in the past few 
years. Initially described as a defined B cell type with immunosuppressive function in chronic 
inflammation, following studies revealed a number of different Breg phenotypes raising the 
suspicion, that they can originate from every subpopulation such as from memory, immature 
or plasma B cells (Sarvaria, Madrigal, and Saudemont 2017; M. Schwartz, Zhang, and 
Rosenblatt 2016; Mauri and Bosma 2012). As consequence, analogous to the well-described 
and previously mentioned Tregs, the term Breg now summarises all B cell subpopulations, 
which inhibit other immune cells und thus promote tumor progression in cancer (Largeot et al. 
2019). Their immunosuppressive effect herein is mainly caused by the secretion of cytokines 
such as IL-10 (Mizoguchi et al. 2002; Bouaziz et al. 2010; Shalapour et al. 2015), which 
downregulates inflammatory cascades through the inhibition of T cell activation by induction of 
STAT3-signalling (Hutchins et al. 2013) as well as of TGF-ß, which transforms resting CD4+ 
T cells into immunosuppressive FoxP3+ Tregs (Olkhanud et al. 2011). Furthermore, Bregs can 
also express IL-35, which stimulates tumor growth directly (Pylayeva-Gupta et al. 2016) or 
suppressive ligands such as PD-L1, thus restricting T cell expansion and differentiation (Khan 
et al. 2015; Shalapour et al. 2015). Additionally, through stimulation of Fcγ-receptors 
expressed on myeloid cells, aggregated antibody complexes secreted by B regs can regulate 
MDSCs and TAMs, which in turn facilitate tumor angiogenesis and tumor cell survival (Andreu 
et al. 2010; Gunderson et al. 2016). Taken together, all these findings outline the pro-
tumorigenic function of regulatory B cells and contribute to explain why depletion of TIL-Bs 
with an anti-CD20 antibody improved response to chemotherapy and suppressed tumor 
growth in mouse models (Affara et al. 2014; Maglioco et al. 2017).  
In contrast to these findings, numerous studies outline an anti-tumorigenic effect of TIL-Bs 
mediated by different strategies. Thus, they can either opsonise tumor cells or inhibit tumor-
associated proteins by secretion of autoantibodies, kill cancer cells directly or activate other 
immune cells through chemokine secretion (Nelson 2010; Tsou et al. 2016). A direct cytotoxic 
effect of B cells indeed has been observed on one hand by secretion of granzyme B upon anti-
BCR and IL-21 stimulation (Hagn et al. 2009; Arabpour et al. 2019) and by expression of 
TRAIL/Apo-2L on the other, which has been shown to be IFN-α-dependently upregulated and 
induced tumor cell killing (Kemp et al. 2004). This effect could even be increased by B cell 
stimulation with an anti-CD40 agonist. Moreover, B cells can additionally function as antigen 
presenting cells (APC) to effectively prime T cells in order to complement absent, inactivated 
or dysfunctional DCs within the TME (Rubtsov et al. 2015). Consistent with these findings, the 
activation of B cells by CD40L to promote their antigen-presenting function has already been 
considered as therapeutic strategy and indeed positively correlated with reduced tumor growth 
by activation of T cells (Wennhold et al. 2017).  Finally, B cells organised within TLS not only 
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have been found to correlate positively with improved survival but to secrete antigen-
experienced antibodies, which were clonally enriched and somatically hypermutated, 
indicating that they actively contributed to an anti-tumor immunity (Coronella et al. 2002; Simsa 
et al. 2005; Nzula, Going and Stott 2003; Hansen et al. 2002; DeFalco et al. 2018). This data 
is also supported by the positive prognostic value of tumor-infiltrating plasma cells found in 
different solid tumor types (Gentles et al. 2015).   
Although immunosuppressive Bregs naturally occur as part of homeostasis protecting tissue 
in chronic inflammation, B cells in cancer are not always initially pro-tumorigenic. Similarly, as 
previously described for Bregs, FoxP3-expressing Tregs in turn suppress the activation and 
proliferation of B cells as well as their antibody production (Kim 2006) and moreover can 
selectively kill antigen-presenting B cells through the secretion of perforins and granzymes 
(Zhao et al. 2006). This demonstrates that T and B cells mutually influence and render each 
other pro-tumorigenic when exposed to an immunosuppressive TME. Additionally, they are 
further influenced by MDSCs, TAMs and the tumor cells themselves. In conclusion, analogous 
to T cells, which are differentially investigated to function as predictive markers or therapeutic 
agents (Balermpas et al. 2014; Pagès et al. 2018), TIL-Bs need to be judged the same way. 
Whereas tumor-infiltrating T cells have been extensively studied in the past, the focus on B 
cells only raised recently. Thus, more comprehensive knowledge is crucially needed to better 
understand the different B cell subsets and their role in the TME. Although in some cases 
frequency of TIL-Bs correlated with decreased prognosis, TIL-B antibody repertoires have 
been shown to be a promising source of tumor-specific antibodies (Nzula et al. 2003; DeFalco 
et al. 2018). Thus, the TIL-B antibody repertoire could provide valuable knowledge about the 
humoral anti-tumor response in cancer patients and may lead to the discovery of novel cancer-
specific target proteins. 
1.6 TILs in head and neck cancer 
Cancers of the head and neck are one of the most common cancer types worldwide with more 
than 800.000 new cases per year (Bray et al. 2018) and compromise malignancies of various 
anatomical structures within the sinonasal tract, oral cavity, pharynx and larynx. More than 
90% of all cases are head and neck squamous cell carcinomas (HNSCC), whereas other types 
such as adenocarcinomas are rare (Pai and Westra 2009). The major risk factors for HNSCC 
are long and intense tobacco smoking as well as frequent consumption of alcohol (Pelucchi et 
al. 2008), which probably serves as solvent and thus synergistically increases the toxicity of 
carcinogenic substances within the tobacco smoke (Talamini et al. 2002).  Despite smoking 
and alcohol consumption, infection with the human papilloma virus (HPV) is the second major 
risk factor. Indeed, HPV infection can be found in 26% of all HNSCC and herein is significantly 




carcinoma (24%) (Kreimer 2005). The oncogenic HPV types HPV16 and HPV18 herein majorly 
mediate carcinogenesis by expressing the two viral proteins E6 and E7, which inactivate the 
tumor-suppressing transcription factor p53 and the retinoblastoma protein (pRb) (Münger and 
Howley 2002). Under normal cellular conditions, p53 is activated in response to different types 
of cellular stress and consequently promotes cell cycle arrest, senescence and apoptosis 
(Wang and El-Deiry 2007). Interestingly, its gene TP53 has been found to be highly mutated 
in different types of cancer as well as in tobacco-induced HNSCC, demonstrating its crucial 
role in tumor suppression (Smeby et al. 2019; Lukas, Niu, and Press 2000; Fagin et al. 1993; 
Brennan et al. 1995). The nuclear pRb in its dephosphorylated form inhibits entry of the S-
phase mediating cell cycle arrest (Cobrinik et al. 1992). In HPV-infection, oncoproteins E6 and 
E7 directly interact with p53 and pRb to form complexes leading to their functional inactivation 
and ubiquitin-dependent degradation, thus facilitating tumor cell survival and increased 
proliferation (Werness et al. 1990; Scheffner et al. 1990; Boyer et al. 1996). As consequence 
of a feedback loop upon pRb inactivation, the cyclin-dependent kinase inhibitor p16, which 
prevents phosphorylation of pRb (Li et al. 1994) is overexpressed and thus widely used as 
reliable marker for HPV-infection in HNSCC (Klussmann et al. 2003; Smeets et al. 2007). 
Furthermore, high levels of p16 have been found to correlate with improved patient outcome 
(Weinberger 2004), whereas loss of p16 by deletion, mutation or promoter hypermethylation 
leads to worse prognosis (Reed et al. 1996; Namazie et al. 2002). Interestingly, although HPV-
infection increases the risk for HNSCC development and in the course of disease metastases 
occur more frequently, patients suffering from HPV-induced HNSCC often show prolonged 
survival (Ang et al. 2010) and a better response to therapy compared to HPV-negative HNSCC 
(Lassen et al. 2011; Ang et al. 2010; Fakhry et al. 2008). Due to the close proximity to lymphatic 
tissue of the Waldeyer’s ring and the frequent occurrence of related viral infection, HNSCC 
has been found to be one of the most highly infiltrated tumor types, which contributes to explain 
the observed improved survival (Mandal et al. 2016; Lei et al. 2016). Although infiltration rates 
are high in HNSCC, a large proportion of present immune cells fail to effectively suppress 
tumor growth due to immunoediting as discussed before. As consequence, dysfunctional T 
cells and abnormal T cell signalling have been widely observed in HNSCC and were often 
accompanied by reduced lymphocyte proliferation and frequent apoptosis (Reichert et al. 
2002). Additionally, HNSCC patients show lower counts of T cells and mature DCs within the 
blood (Kuss 2004; Almand et al. 2000) but higher concentrations of immature MDSCs inhibiting 
T cells and supporting tumor progression (Chikamatsu et al. 2012). Notably, Tregs found within 
the immune infiltrate of HNSCC showed higher expression levels of PD-1, CTLA-4 and TIM-3 
compared to Tregs found within the peripheral blood (Jie et al. 2013) and an increased 
expression of Fas-ligand on tumor cells has been reported to induce apoptosis in T cells 
(Gastman et al. 1999). In summary, the rich immune infiltrate in combination with the highly 
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immunosuppressive TME in HNSCC strongly indicate that HNSCC patients may particularly 
benefit from immunotherapy. Indeed, both prophylactic (Markowitz et al. 2014) and therapeutic 
cancer vaccines (Yang et al. 2017) as well as the anti-EGFR antibody cetuximab (M. H. Cohen 
et al. 2013) are already approved and widely used demonstrating their potential in HNSCC 
therapy. Nevertheless, most available therapeutic strategies still suffer from moderate to low 
response rates in some patient proportions. Adjunctions are believed to overcome this 
limitation and have already been shown to result in improved outcome compared to single 
strategies. Thus, targeting EGFR with cetuximab together with radiation (Bonner et al. 2006), 
application of therapeutic vaccines accompanied by PD-1 checkpoint blockade (Massarelli et 
al. 2019) and combination of the two checkpoint inhibitors nivolumab and ipilimumab (Schwab 
et al. 2018) for instance demonstrated that immunotherapies ideally complement each other 
as well as conventional therapies. HNSCC is a highly complex disease and its 
immunosuppressive TME, the broad variety of anatomical structures and the striking 
differences between HPV+ and HPV- HNSCC constitute many challenges for cancer therapy. 
Nevertheless, the high potential of immunotherapy in HNSCC outlines the urgent need of 
further investigations of the TME and related immune cells to improve therapeutic strategies 
and to discover novel therapeutic targets and antibodies. 
1.7 Aim of this study 
TIL-Bs have been shown to contribute to an anti-tumor immunity, deliver anti-tumor antibodies 
and to correlate with improved survival of patients suffering from different types of cancer. 
Since head and neck cancers belong to the most highly infiltrated cancer types, patients often 
benefit from immunotherapy aiming to redirect their own immune response. However, further 
development of these therapeutic strategies is decisively limited by the discovery of novel 
tumor-specific antibodies and targets. This study aimed to access the antibody repertoire of B 
cells infiltrating head and neck cancer. Antibody gene libraries are constructed based on TIL-
Bs isolated from fresh tumor specimens and analysed to investigate their characteristics. Using 
the phage display technology, antibodies are selected on both a well-known tumor marker and 
a head and neck cancer cell line. The isolated antibodies are characterised, and the respective 
target proteins are identified by mass spectrometry to test if the TIL-B antibody repertoire can 




2. Material and methods 
2.1 Material 
2.1.1 Consumables 
The consumables used in this study are listed in Table 1.  
Table 1: List of consumables 
Material Manufacturer 
Amicon Ultra 0.5 centrifugal filters 30K Merck KGaA, Darmstadt, Germany 
Anti-human IgG Fc capture (AHC) 
Biosensors 
FortéBio, Fremont, USA 
Anti-human Fab-CH1 2nd Generation 
(FAB2G) Biosensors 
FortéBio, Fremont, USA 
Blotting paper Omnilab-Laborzentrum, Bremen Germany 
Costar 96 well assay plate Corning, Inc., New York, USA 
Costar Stripette serological pipettes (2 mL, 
5 mL, 10 mL, 25 mL) 
Corning, Inc., New York, USA 
Cryo tubes with 2D code Greiner Bio-one, Frickenhausen, Germany 
CytoFLEX cleaning agent Beckman Coulter, Brea, USA 
CytoFLEX Daily QC fluorospheres Beckman Coulter, Brea, USA 
CytoFLEX QC Sheath fluid Beckman Coulter, Brea, USA 
Disposable cuvettes Sarsted, Nümbrecht, Germany 
DT-20 eco tube with rotor-stator element IKA, Staufen, Germany 
Erlenmeyer flasks (baffled and non-
baffled) 
DWK Life Sciences, Wertheim, Germany 
Falcon tubes (15 mL, 50 mL) Corning, Inc., New York, USA 
Filter tips (10 µL, 20 µL, 300 µL, 1000 µlL Nerbe plus GmbH, Winsen, Germany 
Fisherbrand cell strainers (40 µm) Thermo Fisher Scientific, Dreieich, Germany 
Freezing container Thermo Fisher Scientific, Dreieich, Germany 
GenePulser electroporation cuvettes  Bio-Rad Laboratories, Munich, Germany 
Injekt-F syringes (1 mL, 10 mL, 20 mL) B. Braun, Melsungen, Germany 
Intellicyt Cleaning solution Sartorius, Göttingen, Germany 
Intellicyt Decontamination solution Sartorius, Göttingen, Germany 
Intellicyt Sheath Fluid Sartorius, Göttingen, Germany 
Intellicyt validation beads (6 peak, 8 peak) Sartorius, Göttingen, Germany 
LightSafe micro tubes (black, 0.5 mL) Sigma-Aldrich, St. Louis, USA 
Low binding tubes 1.5 mL Sarstedt, Nümbrecht, Germany 
Microtiter plate, 96 well, PP, f-bottom Greiner Bio-one, Frickenhausen, Germany 
14 
 
Microtiter plate, 96 well, PP, u-shape Greiner Bio-one, Frickenhausen, Germany 
Microtiter plate, 384 well, PS Greiner Bio-one, Frickenhausen, Germany 
Microtiter plate, 96 well, PP, f-bottom, 
black 
Greiner Bio-one, Frickenhausen, Germany 
Microtiter plate, 96 well, barcoded  Microsynth Seqlab, Göttingen, Germany 
Micro tubes (1.5 mL, 2 mL) Sarstedt 
Micro vials for autosampler TECHLAB, Inc., Blacksburg, USA 
Mini-Protean TGX stain-free gels (12%) Bio-Rad Laboratories, Munich, Germany 
Mini-Protean TGX stain-free gels (4 
– 15%) 
Bio-Rad Laboratories, Munich, Germany 
Minisart sterile filters (0.2 µm, 0.45 µm) Sartorius, Göttingen, Germany 
Multiply Pro 8-strips Sarstedt AG & Co. KG, Nümbrecht, Germany 
Nalgene centrifuge bottles (50 mL, 
500 mL, 1000 mL) 
Sigma-Aldrich, St. Louis, USA 
Neubauer counting chamber BRAND GmbH & Co. KG, Wertheim, 
Germany 
Nitril laboratory gloves Starlab International GmbH, Hamburg, 
Germany 
Nunc Bio Assay dish (pizza plate) Merck KGaA. Darmstadt, Germany 
Nunc cryo tubes (1.8 mL) Thermo Fisher Scientific, Dreieich, Germany 
Petri dish (10 cm) Greiner Bio-one, Frickenhausen, Germany 
Petri dish (60 mm) Sigma-Aldrich, St. Louis, USA 
Petri dish (glass) BRAND GmbH & Co. KG, Wertheim, 
Germany 
Pipette tips (10 µL, 300 µL, 1000 µL) Starlab International GmbH, Hamburg, 
Germany 
Pipette tips 125 µL 384 Tips INTEGRA Biosciences GmbH. Biebertal, 
Germany 
Pipette tips, 300 µL V96 Tips NS INTEGRA Biosciences GmbH. Biebertal, 
Germany 
Pipette tips, 300 µL V96 Tips SF INTEGRA Biosciences GmbH. Biebertal, 
Germany 
Plate sealer aluminium foil HJ-Bioanalytik, Erkelenz, Germany 
Plate sealer breathable foil HJ-Bioanalytik, Erkelenz, Germany 
PVDF membrane, 0.45 µm pore size Carl Roth GmbH, Karlsruhe, Germany 
Reservoir 300 mL sterile, bulk INTEGRA Biosciences GmbH. Biebertal, 
Germany 
Screw cap tubes (2 mL) Sarstedt AG & Co. KG, Nümbrecht, Germany 
Spatula, L-shape VWR International, Radnor, USA 




TC flask T75, Stand., Bel. K. Sarstedt AG & Co. KG, Nümbrecht, Germany 
TC flask T175, Stand., Bel. K. Sarstedt AG & Co. KG, Nümbrecht, Germany 
Whatman Uniplate, 24 deepwell, PP Sigma-Aldrich, St. Louis, USA 
Whatman Uniplate, 96 deepwell, PP Sigma-Aldrich, St. Louis, USA 
 
2.1.2 Equipment 
The equipment used in this study is listed in Table 2. 
Table 2: List of equipment 
Equipment Model Manufacturer 
8-channel pipettes  Research plus (10 µL, 
100 µL, 300 µL) 
VOYAGER 
Eppendorf, Hamburg, Germany 
 
INTEGRA Biosciences GmbH, 
Biebertal, Germany 
96-channel pipette VIAFLO96 INTEGRA Biosciences GmbH, 
Biebertal, Germany 
Blotting device Trans-Blot SD  Bio-Rad Laboratories, Munich, 
Germany 
Centrifuges 5810 R 
Heraeus Pico 17 
 
Heraeus Biofuge Fresco 
 
Sovrall LYNX 4000  
 
Allegra X-15R 
Eppendorf, Hamburg, Germany 
Thermo Fisher Scientific, Dreieich, 
Germany 
Thermo Fisher Scientific, Dreieich, 
Germany 
Thermo Fisher Scientific, Dreieich, 
Germany 
Beckman Coulter, Krefeld, Germany 
Colony picker Qpix Molecular devices, San José, USA 
Disperser Ultra-Turrax  IKA, Staufen, Germany 
Electrophoresis 
chambers 
Mini Protean Tetra cell 
 
PEQLAB 
Bio-Rad Laboratories, Munich, 
Germany  
PEQLAB Biotechnologie GmbH, 
Erlangen, Germany 
Electroporator MikroPulser  Bio-Rad Laboratories, Munich, 
Germany 
Flow cytometer CytoFLEX 
Intellicyt iQue Screener 
Beckman Coulter, Brea, USA 
Sartorius, Göttingen, Germany 
HPLC system Spark Mistral column oven 
L-4000 UV detector 
L-6200A intelligent pump 
Degasi Semi-Prep Plus 
KW-G 6B precolumn 
KW-803 Shodex column  
Autosampler 410 
TECHLAB, Inc., Blacksburg, USA 
TECHLAB, Inc., Blacksburg, USA 
TECHLAB, Inc., Blacksburg, USA 
Biotech, Minneapolis, USA  
TECHLAB, Inc., Blacksburg, USA 
TECHLAB, Inc., Blacksburg, USA 
TECHLAB, Inc., Blacksburg, USA 
Incubators Axon IS-2-K 
SOK3190 
Axon, Kaiserslautern, Germany 








Labnet International, Inc., Edison, USA 
LabWit Scientific, Burwood East, 
Australia 
Kendro Laboratory Products, Hanau, 
Germany 
Magnetic rack DynaMag-2 magnet Thermo Fisher Scientific, Dreieich, 
Germany 
Microplate stacker Biostack BioTek, Friedrichshall, Germany 
Microplate washer HydroFlex  
EL405 
EL406  
TECAN, Crailshaim, Germany 
BioTek, Friedrichshall, Germany 
BioTek, Friedrichshall, Germany 
Microscope IX70 Olympus K. K., Tokyo, Japan 
Microwave Inverter Sharp K. K., Osaka, Japan 
Octet Octet QKe system FortéBio, Fremont, USA 
Photometer ScanDrop² Analytik Jena, Jena, Germany 
Pipettes  Research plus (2.5 µL, 
10 µL, 20 µL, 200 µL, 
1000 µL) 
Eppendorf, Hamburg, Germany 
Pipetting aid Accu-jet pro BRAND GmbH & Co KG, Wertheim, 
Germany 
Plate reader Epoch  BioTek, Friedrichshall, Germany 
Plate sealer Quick-Combi Sealer Plus HJ-Bioanalytik, Erkelenz, Germany 
Power supply PowerPac HC 200 & 300 
 
Bio-Rad Laboratories, Munich, 
Germany 
Rocker Duomax 1030 & 2010 Heidolph Instruments, Schwabach, 
Germany 
Rotator Multi Bio RS-24 BioSan, Riga, Latvia 
Scales Entris Sartorius, Göttingen, Germany 
Sterile bench Heraguard ECO  Thermo Fisher Scientific, Dreieich, 
Germany 




Eppendorf, Hamburg, Germany 
BioSan, Riga, Latvia 
UV illuminator ChemiDoc MP Bio-Rad Laboratories, Munich, 
Germany  
Vortexer Reax top Heidolph Instruments, Schwabach, 
Germany 
Water system Milli-Q UF plus Merck KGaA, Darmstadt, Germany 
 
2.1.3 Chemicals 





Table 3: List of chemicals 
Chemical Manufacturer 
3,3’,5,5’-Tetramethylbenzidine (TMB) Carl Roth GmbH, Karlsruhe, Germany 
3,3’-Diaminobenzidin (DAB) Carl Roth GmbH, Karlsruhe, Germany 
7-Aminoactinomycin D (7-AAD) Thermo Fisher Scientific, Dreieich, Germany 
Acetid acid Carl Roth GmbH, Karlsruhe, Germany 
Aceton Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin sodium salt AppliChem GmbH, Darmstadt, Germany 
Bacto tryptone BD Biosciences, Heidelberg, Germany 
Bacto yeast extract BD Biosciences, Heidelberg, Germany 
Bovine serum albumin (BSA) Pan Biotech GmbH, Aidenbach, Germany 
Citric acid Carl Roth GmbH, Karlsruhe, Germany 
Cobalt chloride Carl Roth GmbH, Karlsruhe, Germany 
Coomassie brilliant blue Carl Roth GmbH, Karlsruhe, Germany 
D(+)-glucose-monohydrate Carl Roth GmbH, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Merck KGaA, Darmstadt, Germany 
Dipotassium hydrogen phosphate Carl Roth GmbH, Karlsruhe, Germany 
Disodium hydrogen phosphate 
dihydrate 
Carl Roth GmbH, Karlsruhe, Germany 
Dithiothreitol (DTT) Carl Roth GmbH, Karlsruhe, Germany 
Ethanol absolute VWR International, Radnor, USA 
Ethylenediaminetetraacetic acid Carl Roth GmbH, Karlsruhe, Germany 
Glycerol Carl Roth GmbH, Karlsruhe, Germany 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
Hydrochloric acid Carl Roth GmbH, Karlsruhe, Germany 
Hydrogen peroxide Carl Roth GmbH, Karlsruhe, Germany 
Isopropyl-β-D-1-thiogalactopyranoside 
(IPTG) 
Carl Roth GmbH, Karlsruhe, Germany 
2-Propanol Carl Roth GmbH, Karlsruhe, Germany 
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Kanamycin sulphate Carl Roth GmbH, Karlsruhe, Germany 
LE-Agarose Biozym Scientific GmbH, Oldendorf, Germany 
Lymphoprep Stemcell Technologies, Vancouver, Canada 
Phenylmethylsulfonylfluorid (PMSF) Thermo Fisher Scientific, Dreieich, Germany 
Potassium citrate Carl Roth GmbH, Karlsruhe, Germany 
Potassium chloride Carl Roth GmbH, Karlsruhe, Germany 
Potassium dihydrogen phosphate Carl Roth GmbH, Karlsruhe, Germany 
Propidium iodide Carl Roth GmbH, Karlsruhe, Germany 
Skim milk powder SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Sodium chloride Carl Roth GmbH, Karlsruhe, Germany 
Spam agar WIECHERS & HELM GmbH & Co. KG, 
Hamburg, Germany 
Sulfuric acid Carl Roth GmbH, Karlsruhe, Germany 
Tetracycline hypochloride AppliChem GmbH, Darmstadt, Germany 
Tris(hydroxymethyl)aminomethane Carl Roth GmbH, Karlsruhe, Germany 
TRIzol reagent Thermo Fisher Scientific, Dreieich, Germany 
Trypan blue Merck KGaA, Darmstadt, Germany 
Trypsin/EDTA Biochrom GmbH, Berlin, Germany 
Tween20 Thermo Fisher Scientific, Dreieich, Germany 
 
2.1.4 Enzymes, markers and buffers 
All commercial enzymes, markers and buffers used in this study are listed in Table 4. 
Table 4: Enzymes, markers and buffers 
Enzymes, markers and buffers Manufacturer 
Endonucleases 
AgeI-HF New England Biolabs, Frankfurt am Main, 
Germany 





BsmBI New England Biolabs, Frankfurt am Main, 
Germany 
BssHII New England Biolabs, Frankfurt am Main, 
Germany 
Collagenase G  Sekisui Diagnostics GmbH, Burlington, 
USA 
Collagenase H Sekisui Diagnostics GmbH, Burlington, 
USA 
Esp3I New England Biolabs, Frankfurt am Main, 
Germany 
DNase I Merck KGaA, Darmstadt, Germany 
DraIII-HF New England Biolabs, Frankfurt am Main, 
Germany 
HindIII-HF New England Biolabs, Frankfurt am Main, 
Germany 
MluI-HF New England Biolabs, Frankfurt am Main, 
Germany 
NcoI-HF New England Biolabs, Frankfurt am Main, 
Germany 
NheI-HF New England Biolabs, Frankfurt am Main, 
Germany 
NotI-HF New England Biolabs, Frankfurt am Main, 
Germany 
PacI New England Biolabs, Frankfurt am Main, 
Germany 
Ligases 
T4 DNA ligase Promega GmbH, Mannheim, Germany 
Polymerases 
GoTaq G2 DNA Polymerase Promega GmbH, Mannheim, Germany 
Q5 Hot Start High Fidelity DNA Polymerase New England Biolabs, Frankfurt am Main, 
Germany 
Buffers 




Gel Loading Dye Purple (6x) New England Biolabs, Frankfurt am Main, 
Germany 
Green GoTaq Flexi Reaction Buffer (5x) Promega GmbH, Mannheim, Germany 
Laemmli Sample Buffer (4x) Bio-Rad Laboratories, Munich, Germany  
NP40 Cell Lysis Buffer Thermo Fisher Scientific, Dreieich, 
Germany 
Q5 Reaction Buffer (5x) New England Biolabs, Frankfurt am Main, 
Germany 
T4 DNA Ligase Buffer (10x) Promega GmbH, Mannheim, Germany 
Tris/Glycine/SDS (TGS) running buffer (10x) Bio-Rad Laboratories, Munich, Germany  
Protein & DNA standards 
GeneRuler 1 kb DNA ladder Thermo Fisher Scientific, Dreieich, 
Germany 
Precision Plus Protein Standard all blue Bio-Rad Laboratories, Munich, Germany 
Precision Plus Protein Standard unstained Bio-Rad Laboratories, Munich, Germany 
Protein Standard Mix 15 – 600 kDa for SEC Merck KGaA, Darmstadt, Germany 
Others 
Alkaline phosphatase, calf intestinal (CIP) New England Biolabs, Frankfurt am Main, 
Germany 
Halt protease inhibitor cocktail (100x) Thermo Fisher Scientific, Dreieich, 
Germany 
HDGreen DNA Stain INTAS Science Imaging Instruments 
GmbH, Göttingen, Germany 
 
2.1.5 Commercial kit systems  
All used commercial kit systems are listed in Table 5. 
Table 5: Kit systems 
Kit system Manufacturer  
CellTrace CFSE Cell Proliferation Thermo Fisher Scientific, Dreieich, Germany 
EasySep Release Human CD19 Positive 
Selection Kit 




NucleoBond Xtra Midi Macherey-Nagel, Düren, Germany 
NucleoSpin Gel and PCR Clean up Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid Transfection-grade Macherey-Nagel, Düren, Germany 
Superscript IV First Strand Synthesis 
System 
Thermo Fisher Scientific, Dreieich, Germany 
Direct-zol RNA MiniPrep Plus Zymo Research, Irvine, USA 
 
2.1.6 Commercial antibodies and proteins  
All used commercial antibodies are listed in Table 6. The myc-specific antibodies TUN219-
2C1 (human-Fc) and TUN219-2C1 (mouse-Fc) were produced and purified in-house. 
The used commercial proteins are listed in Table 7. 
Table 6: Commercial antibodies 
Antibody (clone) Species Conjugation Manufacturer 
Anti-human CD19 antibody 
(SJ25C1) 
Mouse FITC BioLegend, San Diego, 
USA 
Anti-human CD45 antibody 
(HI30) 
Mouse APC BioLegend, San Diego, 
USA 
Anti-mouse IgG HRP 
(polyclonal) 
Goat HRP Merck KGaA, Darmstadt 
Germany 
Anti-human IgG HRP 
(polyclonal) 
Goat HRP Merck KGaA, Darmstadt 
Germany 
Anti-pIII(g3p)-antibody (10C3) Mouse - MoBiTec GmbH, 
Göttingen, Germany 
Anti-human IgG (H+L) Cross-
adsorbed Secondary antibody 
(polyclonal) 
Goat Alexa Fluor 647 Thermo Fisher Scientific, 
Dreieich, Germany 
Anti-mouse IgG (H+L) Cross-
adsorbed Secondary antibody 
(polyclonal) 
Goat Alexa Fluor 647 Thermo Fisher Scientific, 
Dreieich, Germany 
CD9 antibody IHC-plus 
(MM2/57) 
Mouse - LifeSpan BioSciences, 
Inc., Seattle, USA 
Human Integrin α3/CD49c 
antibody (IA3) 










Mouse - R&D Systems, 
Minneapolis, USA 
 
Table 7: Commercial proteins 
Protein Manufacturer 
Human MMP-9 / CLG4B Protein (His Tag) Sino Biological, Inc., Peking, China 
Human Transferrin Receptor / TFRC / CD71 
Protein (His Tag) 
Sino Biological, Inc., Peking, China 
Recombinant Human CD9 protein (Tagged) 
ab152262 
Abcam, Cambridge, UK 
Recombinant Human Integrin α3β1/VLA-3 R&D Systems, Minneapolis, USA 
Recombinant Human MMP-9  R&D Systems, Minneapolis, USA 
 
2.1.7 Bacteria and bacteriophage  
The used bacterial strains and bacteriophage are listed in Table 8. 
Table 8: Bacteria and bacteriophage 
Strain Genotype Manufacturer/Reference 
E. coli ER2738 [F'proA+B+ lacIq Δ(lacZ)M15 




E. coli XL1-Blue-MRF’ ∆(mcrA)183 ∆(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr)] 
Agilent, Santa Clara, USA 
E. coli TG1 [F' traD36 proAB lacIqZ ΔM15] 
supE thi-1 Δ(lac-proAB) Δ(mcrB-
hsdSM)5(rK - mK -) 
Lucigen Corporation, 
Middleton, USA 
M13K07 - Vieira and Messing 1987 
Hyperphage 
(M13K07ΔgIII) 





2.1.8 Mammalian cell lines 
All cell lines used in this study are listed in Table 9. 
Table 9: Mammalian cell lines 
Cell line Organism Tissue Disease Reference 
HEK293 Human Kidney - ATCC, Manassas, USA 
FaDu Human Pharynx Squamous cell 
carcinoma 
ATCC, Manassas, USA 




ATCC, Manassas, USA 
CHO-K1 Hamster Ovary - ATCC, Manassas, USA 
 
2.1.9 Gene syntheses 
All gene syntheses used in this work were provided by Integrated DNA Technologies 
(Coralville, USA). Sequences of human CD9, human CD71 and human MMP-9 were obtained 
from public database (https://www.uniprot.org/). 
2.1.10 Plasmids and oligonucleotides 
All plasmids and oligonucleotides used in this work are listed in Table 10. Oligonucleotides 
used for library construction were obtained from a previous publication (Kügler et al. 2018). 
Primers for cloning of IgG (2.2.2.7) were designed based on the respective antibody sequence 
containing the required restriction sites and provided by Biolegio (Nijmegen, Netherlands). 
Oligonucleotides used for standard colony PCR and gBlock amplification are listed in Table 
11. 
Table 10: Phagemid and plasmids 
Plasmid Description Reference 
pHAL30 Phagemid, coding for protein:pIII fusion, 
lacZ promoter, pelB leader sequence, 
Yol-linker 
Kügler et al. 2015 
pCSE2.6-mIgG2a-Fc-XP Mammalian expression vector for scFv-
Fc format, mouse2a-Fc, pCSE-
backbone, CMV promoter 
Based on pCSE2.5 
(Jäger et al. 2013) 
pCSEH1c Mammalian expression vector for IgG-
HC, human-CH1, -CH2 & -CH3, pCSE-
backbone, CMV promoter 
Based on pCSE2.5 
(Jäger et al. 2013) 
24 
 
pCSL3k Mammalian expression vector for IgG-LC 
(kappa), human-CL-lambda, pCSE-
backbone, CMV promoter 
Based on pCSE2.5 
(Jäger et al. 2013) 
pCSL3l Mammalian expression vector for IgG-LC 
(lambda), human-CL-lambda, pCSE-
backbone, CMV promoter 
Based on pCSE2.5 
(Jäger et al. 2013) 
pCSE2.6-TM-GFP Mammalian expression vector coding for 
a protein-GFP fusion with intermediate 
transmembrane domain, pCSE-
backbone, CMV promoter  
Based on pCSE2.5 
(Jäger et al. 2013) 
pCSE2.6-GFP Mammalian expression vector coding for 
a protein-GFP fusion, pCSE-backbone, 
CMV promoter  
Based on pCSE2.5 
(Jäger et al. 2013) 
 
Table 11: Oligonucleotides 
ID Description Sequence (5’-3’) 
YP11 MHgIII_r CTAAAGTTTTGTCGTCTTTCC 
YP125 MHLacZ-Pro_f GGCTCGTATGTTGTGTGG 
YP411 Tor-pCMV-mIgG01_Fc-seq-r CAGATGGCTGGCAACTAG  
YP886 CM2_F CGCAAATGGGCGGTAGGCGTG 
YP1371 Gene_amp-fwd GGGTAGGTAGGTAGGTAGGG 
YP1461 Gene_amp-rev CGCTATGCGTATCGCTATCGC 
 
2.1.11 Buffers and solutions 
The buffers and solutions used in this study are listed in Table 12. 
Table 12: Buffers and solutions 
Buffer/solution Component Concentration Solvent 
1 N sulfuric acid Sulfuric acid 500 mM Ultrapure water 
2 M Glucose Glucose 2 M Ultrapure water 
10x DTT 1,4’-Dithiothreitol 250 mM Ultrapure water 








100 mg/mL Ampicillin 1% (v/v) 
10000x PI Propidium iodide 1% (w/v) Ultrapure water 





Agarose gel Agarose 









BSA-PBST Bovine serum albumin 1% (w/v) PBST 
Coomassie staining 
solution 







DAB stock 3’-Diaminobenzidine 2.5% (w/v) Ultrapure water 
DAB reaction buffer CoCl2 0.02% (w/v) PBS 









FACS buffer EDTA 
Fetal bovine serum 
2 mM  
5% (v/v) 
PBS 
MilliQ-Tween Tween20 0.05% (v/v) Ultrapure water 
MPBST Skim milk powder 2% (w/v) PBST 
PBST Tween20 0.05% (v/v) PBS 

























PMSF PMSF 100 mM 2-Propanol 
SDS running buffer 10x TGS running buffer 10% (v/v) Ultrapure water 


























Trypsin (10 µg/mL) Trypsin 0.003% (w/v) PBS 
 
2.1.12 Media and supplements  
2.1.12.1 Media and supplements for bacterial culture 
Recipes and composition of used media (Table 13 and Table 15) and the respective 
supplements (Table 14) are listed below.  
Table 13: Recipes for basic media  
Medium Component Concentration Solvent 










optional: Spam agar 1.5% (w/v) 
LB medium Bacto tryptone 
Yeast extract 
NaCl 






SOB medium Bacto tryptone 














Table 14: Concentration of media supplements 
Supplement Stock concentration Final concentration 
Ampicillin 100 mg/mL 100 µg/mL 
Tetracycline 10 mg/mL 20 µg/mL 
Kanamycin 50 mg/mL 50 µg/mL 
Glucose 2 M 100 mM 
IPTG 1 M 50 µM 
 
Table 15: Composition of used media 
Medium Supplement Final concentration 























2xYT-T Tetracycline 20 µg/mL 












2.1.12.2 Media and solutions for mammalian cell culture  
All media and supplements used in this study are listed in Table 16. FBS was heat-inactivated 
at 55°C for 1 h, aliquoted and stored at -20°C prior to use.  
Table 16: Commercial media and solutions 
Medium/solution Manufacturer 
FBS superior Biochrom GmbH, Berlin, Germany 
Penicillin/Streptomycin Biochrom GmbH, Berlin, Germany 
RPMI 1640 Biochrom GmbH, Berlin, Germany 
Trypsin/EDTA Biochrom GmbH, Berlin, Germany 
Versene (EDTA) Biozym Scientific GmbH, Oldendorf, Germany 
VLE-DMEM Biochrom GmbH, Berlin, Germany 
 
2.1.13 Software 





Table 17: Software 
Software Application Source 
Clarity Data acquisition with 
HPLC system 
DataApex, Prague, Czech Republik 
CytExpert Data acquisition with 
CytoFLEX 
Beckman Coulter, Brea, USA 
 
FlowLogic Analysis of flow 
cytometric data 
Miltenyi BioTec GmbH, Bergisch 
Gladbach, Germany 
ForeCyt  Data acquisition and 
analysis with Intellicyt 
iQue Screener 
Sartorius, Göttingen, Germany 
Gen5 ELISA reader BioTek Instruments, Vermont, USA 
GraphPad Prism7 Data and statistical 
analysis 
https://www.graphpad.com/ 
IMGT Analysis of antibody 
sequences 
http://www.imgt.org/ 
Liquid Handling Control Microplate washer 
EL406 
BioTek Instruments, Vermont, USA 
Microsoft office Data evaluation and 
writing 
Microsoft Corporation, Washington 
USA 
NCBI Literature research https://www.ncbi.nlm.nih.gov/ 
Octet DataAcquisition11 Operation and data 
acquisition with Octet 
System 
FortéBio, Fremont, USA 
Octet DataAnalysis11 Analysis of Octet 
System data 
FortéBio, Fremont, USA 
Protein atlas Protein database https://www.proteinatlas.org/ 
UGENE Sequence analysis and 
alignment 
Unipro LLC, Novosibirsk, Russia 
UniProt Protein database https://www.uniprot.org/ 
Vortex Data evaluation Dotmatics, Bishop’s Stortford, UK 
Zotero Literature management 





2.1.14 Tumor material 
Tumor specimens were obtained from head and neck cancer patients in the course of their 
curative surgery and kindly provided by Prof. Dr. Andreas Gerstner (Städtisches Klinikum 
Braunschweig, Germany). Regardless of their age, gender and previous therapy patients were 
included if they gave their free and informed consent. This study was examined and approved 
by the ethics committee of the faculty of life sciences (Technische Universität Braunschweig, 
Germany) (ID: FV-2016-10).  
 
2.2 Methods 
2.2.1 Microbiological methods 
2.2.1.1 Cultivation of bacteria 
Bacterial cultures were inoculated either from glycerol stocks of from single clones on agar 
plates and cultivated in 2xYT or LB medium supplemented with the appropriate antibiotics. If 
bacteria carried a pHAL-construct, 100 mM glucose was added to the medium. Cells were 
incubated overnight (16-18 h) at 37°C and 250 rpm.  
2.2.1.2 Plating 
Upon transformation or infection with phage, bacteria were plated on 2xYT or LB agar plates 
supplemented with 100 mM glucose and the respective antibiotics using disposable spatula. 
Plates were incubated overnight (16-18 h) at 37°C.   
2.2.1.3 Storage of bacteria 
Bacteria grown on agar plates were stored at 4°C for up to one week. For long-term storage 
of liquid cultures, glycerol stocks of 1 mL (tubes) or 180 µL (microtiter plate) were prepared by 
adding a final volume of 20% glycerol (v/v). Stocks were snap frozen in liquid nitrogen and 
stored at -80°C.  
2.2.1.4 Preparation of plasmid DNA 
Plasmid DNA was isolated and purified either in small (mini preparation) or in large scale (midi 
preparation). Plasmid-containing bacteria were cultivated overnight at 37°C and 250 rpm in 
5 mL (mini) or 100 mL (midi) LB medium supplemented with the appropriate antibiotics 
(100 mM glucose for pHAL-constructs). Cultures were transferred into 1.5 mL tubes or 50 mL 
falcon tubes and centrifuged at 15.000xg for 30 s or at 3220xg for 10 min, respectively. 
Supernatants were discarded and cell pellets were used for plasmid preparation using the 
NucleoSpin Plasmid Mini Kit or the NuceloBond Plasmid Midi Kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s protocol. DNA was eluted with ultrapure water and 
concentration was determined using a microvolume spectrophotometer. DNA was stored at 




2.2.1.5 Transformation of bacteria 
2.2.1.5.1 Heat-shock transformation 
Within cloning of DNA constructs, chemically competent XL1-Blue-MRF’ cells were 
transformed by the heat-shock method. 50 µL cells were slowly thawed on ice, mixed with the 
ligation and incubated on ice for 15 min. Heat shock was applied by incubating the cells at 
42°C for 60 s followed by incubation on ice for 2 min. Cells were immediately resuspended in 
150 µL pre-warmed SOC medium and incubated at 37°C and 650 rpm for 1 h. The whole cell 
suspension was plated on 2xYT-GA agar plates and incubated overnight at 37°C. 
2.2.1.5.2 Electroporation  
To increase transformation efficacies within antibody library cloning, electrocompetent bacteria 
were transformed by electroporation. To prevent arcing during electric pulsing ligation was 
desalted prior to electroporation. Reaction mix was transferred into Amicon Ultra Centrifugal 
Filters (30K) (Merck KGaA, Darmstadt, Germany), topped up with ice-cold ultrapure water and 
centrifuged at 14000xg for 10 min. Flow-through was discarded and procedure was repeated 
three times. Sample was eluted by centrifuging the inverted column into a fresh tube at 2000xg 
for 2 min. Electrocompetent cells (ER2738 or XL1-Blue-MRF’) were slowly thawed on ice and 
mixed with the eluted ligation. Cells were incubated on ice for 2 min, transferred into an ice-
cold electroporation cuvette and electric pulse was applied with 1.7 kV.  Cells were 
immediately resuspended in 1 mL pre-warmed SOC medium, transferred into a 1.5 mL tube 
and incubated at 37°C and 650 rpm for 1 h. 10 µL of cell suspension was saved for titration 
(2.2.3.3). Remaining volume was plated on 2xYT-GAT pizza plates and incubated overnight 
at 37°C (XL1-Blue-MRF’) or 30°C (ER2738).  
 
2.2.2 Molecular biological methods 
2.2.2.1 Polymerase-chain reaction 
2.2.2.1.1 Colony-PCR 
Amplification of inserts by colony-PCR was used to confirm correct insert size and to determine 
insert rates of antibody libraries upon transformation. GoTaq G2 DNA polymerase (Promega, 
Mannheim, Germany) was used according to the protocol provided by the manufacturer. 
Primer sets were selected respective to the vector backbone (Table 18) and added to the 
reaction mix. Single colonies were picked from agar plates and used as templates for PCR 
reaction, which was performed in a thermal cycler using the protocol suggested by the supplier. 




Table 18: Primer sets for colony PCR 
Vector backbone  Primer set 
pHAL YP11 / YP125 
pCSE YP411 / YP886 
 
2.2.2.1.2 Amplification of genes 
Within cloning of DNA, PCR was used to amplify genes. Plasmid DNA or DNA syntheses 
containing the desired sequence was used as template. For amplification of genes, Q5 Hotstart 
High Fidelity DNA Polymerase (New England Biolabs, Frankfurt am Main, Germany) was used. 
Reaction mix was prepared as suggested by the manufacturer. Oligonucleotide primers 
flanking the desired DNA fragment were selected respective to the given template and added 
to the reaction mix. PCR was performed according to the supplied protocol in a thermal cycler 
and amplification of correct DNA fragments was confirmed in agarose gel electrophoresis 
(2.2.2.2).   
2.2.2.2 Agarose gel electrophoresis 
DNA fragments were separated by size for analysis using agarose gel electrophoresis. DNA 
samples were mixed with DNA loading dye and loaded on a 1.5% agarose gel (w/v) 
supplemented with HD Green DNA Stain. The GeneRuler 1 kb Plus DNA ladder (Thermo 
Fisher Scientific, Dreieich, Germany) was used as reference for fragment size evaluation. Gel 
electrophoresis was run at 130 V for 30 min and gels were documented in a camera system 
under UV light.  
2.2.2.3 Digestion and dephosphorylation of DNA 
For cloning DNA fragments were digested with appropriate endonucleases. All endonucleases 
used in this study were provided by New England Biolabs (Frankfurt am Main, Germany) and 
digestions were performed according to the manufacturer’s protocol. Digested plasmid DNA 
additionally was dephosphorylated to prevent undesired re-ligation using CIP (New England 
Biolabs, Frankfurt am Main, Germany) as suggested by the supplier. Upon digestion, DNA was 
purified (2.2.2.4), concentration was determined using a microvolume spectrophotometer and 
stored at -20°C.    
2.2.2.4 Purification of amplified and digested DNA  
Amplified DNA was purified upon amplification or digestion for further cloning. If DNA was 
separated by size in agarose gel electrophoresis first, the desired bands of expected size were 
excised from gel using a disposable scalpel and transferred into a 2 mL reaction tube. 200 µL 
NTI buffer per 100 mg gel were added and sample was incubated at 55°C for 20 min until gel 




reaction mix, 200 µL NTI DNA binding buffer were added per 100 µL sample volume. DNA 
was purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, Düren, 
Germany) according to the instruction given by the supplier. DNA was eluted with ultrapure 
water and concentration was determined using a microvolume spectrophotometer. DNA was 
stored at -20°C.  
2.2.2.5 Cloning of GFP-fusion proteins 
Genes of human MMP-9, CD9 and CD71 were obtained from public database 
(https://uniprot.org/) and synthesised (Integrated DNA Technologies, Coralville, USA). Genes 
were amplified by Q5-PCR (2.2.2.1.2), digested with PacI/NotI (CD9 and CD71) or BssHII/NotI 
(MMP-9) (2.2.2.3) and analysed in agarose gel electrophoresis (2.2.2.2). Desired bands were 
excised, purified (2.2.2.4) and ligated with the respective target vector, which was previously 
digested with the same enzymes and dephosphorylated. CD9 and CD71 were cloned into 
pCSE2.6-GFP, whereas MMP-9 was ligated with pCSE2.6-TM-GFP, which additionally adds 
a transmembrane domain between protein and GFP. Ligations were performed using the T4 
DNA Ligase (Promega, Mannheim, Germany) according to the manufacturer’s protocol 
adjusting a molar ratio of 3:1 (insert to vector), incubated at toom temperature for 3 h and used 
for heat-shock transformation of chemically competent bacteria (2.2.1.5.1). Successful cloning 
was confirmed by colony PCR (2.2.2.1.1) and sanger sequencing (2.2.2.8.1).  
2.2.2.6 Cloning of scFv-Fc  
For cloning of scFv-Fc fragments, whole scFv-sequences were amplified directly from 
phagemid and cloned into target vector pCSE2.6-mIgG2a-Fc-Xp. Purified plasmid DNA (1-10 
ng) of the appropriate clone was used as template for Q5-PCR (2.2.2.1.2). Amplified DNA was 
digested with NcoI and NotI (2.2.2.3) and analysed in agarose gel electrophoresis (2.2.2.2). 
Desired band (~850 bp) was excised, purified from gel (2.2.2.4) and ligated with the previously 
NcoI/NotI-digested, CIP-treated target vector. Ligations were performed using the T4 DNA 
Ligase (Promega, Mannheim, Germany). Reactions were prepared according to the 
manufacturer’s protocol adjusting a molar ratio of 3:1 (insert to vector), incubated at room 
temperature for 3 h and used for heat-shock transformation of chemically competent bacteria 
(2.2.1.5.1). Successful cloning was confirmed by colony PCR (2.2.2.1.1) and sanger 
sequencing (2.2.2.8.1).  
2.2.2.7 Cloning of IgG 
For cloning of IgG, variable domains of heavy and light chain were amplified separately and 
cloned into pCSEH1c (heavy chain) or pCSL3k/pCSL3l (light chain), respectively. Overnight 
culture (1 µL) of the appropriate clone was used as template for Q5-PCR (2.2.2.1.2). Two PCR 
reactions per clone were performed to amplify both the VH and VL of each antibody using the 
appropriate primers, which were designed based on the respective antibody sequence and 
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added the required restriction sites. Amplified insert DNA and target vectors were digested 
with the respective enzymes (Table 19) (2.2.2.3) and purified (2.2.2.4). Ligations were 
performed using the T4 DNA Ligase (Promega, Mannheim, Germany). Reactions were 
prepared according to the manufacturer’s protocol adjusting a molar ratio of 3:1 (insert to 
vector), incubated at room temperature for 3 h and used for heat-shock transformation of 
chemically competent bacteria (2.2.1.5.1). Successful cloning was confirmed by colony PCR 
(2.2.2.1.1) and sanger sequencing (2.2.2.8.1).    
 
Table 19: Combination of enzymes for IgG cloning 
DNA Target vector Enzymes 
VH pCSEH1c BssHII / NheI 
VL (kappa) pCSL3k AgeI / BsiWI 
VL (lambda) pCSL3l AgeI / DraIII 
 
 
2.2.2.8 DNA sequencing  
2.2.2.8.1 Single tube sequencing  
Purified plasmid DNA containing the sequence of interest was diluted in ultrapure water 
(80 ng/µL) and sent to Microsynth SeqLab (Göttingen, Germany) for Sanger sequencing.  
2.2.2.8.2 Plate sequencing  
Sequencing plates (96-well) were prepared with 150 µL 2xYT medium supplemented with the 
appropriate antibiotics (100 mM glucose for pHAL constructs). Each well was inoculated with 
a clone carrying the DNA of interest and incubated at 37°C and 800 rpm for 3 h. Plate was 
sealed and sent to Microsynth SeqLab (Göttingen, Germany) for Sanger sequencing.   
2.2.2.8.3 Next generation sequencing (NGS)  
For next generation sequencing of scFv-libraries, plasmid DNA was purified from 1 mL glycerol 
stock upon library cloning (2.2.3.3). NGS sequencing, analysis and raw data processing was 
kindly performed by Dr. Thomas Clarke (EMD Serono, Billerica, USA). In detail, amplicon 
libraries were prepared via PCR and adapters for immobilisation and sequencing were 
annealed to both the 3’ and the 5’ ends. Libraries were then bridge-amplified for cluster 
formation and sequenced by synthesis in a MiSeq Illumina sequencer. Raw data was cleared 




2.2.3 Construction of recombinant TIL-B antibody libraries  
2.2.3.1 Processing of tumor samples 
Specimens of primary tumors derived from head and neck cancer patients were obtained 
freshly upon curative surgery and kindly provided by Prof. Dr. Andreas Gerstner (Städtisches 
Klinikum Braunschweig, Germany). After determining the wet weight, tissue was manually 
minced using surgical scissors and digested with 30 U DNaseI, 3 U collagenase G and 10 U 
collagenase H in DNaseI reaction buffer for 1 h at 37°C. If sample weight was ≥250 mg, 
digested tissue was additionally homogenised in a disperser (IKA, Staufen, Germany). 
Samples <250 mg were directly passed through a 40 µm cell strainer in order to obtain a single 
cell suspension and 20 µL were used for counting the cells in a Neubauer chamber (2.2.6.3). 
In total 105 cells were aliquoted into a 1.5 mL tube, pelleted by centrifugation (500xg, 10 min) 
and resuspended in PBS. Cells were stained with fluorochrome-conjugated anti-CD19 (FITC) 
and anti-CD45 (APC) antibodies (BioLegend, San Diego, USA), which were diluted in 1:400 in 
FACS buffer. Upon 15 min of incubation on ice, cells were washed once, resuspended in FACS 
buffer and analysed in a flow cytometer (2.2.5.7). The amount of detected CD19+/CD45+ 
B cells in relation to the total number of counted cells was calculated to estimate the theoretical 
B cell count within the whole sample.  
2.2.3.2 Isolation of B cells 
CD19+ B cells were isolated from tumor tissue cell suspension using the EasySep Release 
Human CD19 Positive Selection Kit (Stemcell Technologies, Vancouver, Canada) according 
to the manufacturer’s protocol. Upon isolation, eluted B cells were transferred into a 1.5 mL 
tube, pelleted by centrifugation at 500xg for 5 min, resuspended in 1 mL TRIzol reagent 
(Thermo Fisher Scientific, Dreieich, Germany) and stored at -80°C. 
2.2.3.3 Construction of antibody gene libraries 
B cells isolated from tumor samples (2.2.3.2) were thawed and total mRNA was isolated using 
the Direct-zol RNA MiniPrep Plus kit system (Zymo Research, Irvine, USA) according to the 
instructions provided by the manufacturer. Antibody gene libraries were constructed as 
described previously (Kügler et al. 2018). In detail, cDNA was synthesised from total RNA by 
reverse transcription and used as template for antibody gene amplification. Variable antibody 
domains were amplified and cloned successively into phagemid pHAL30. Transformed 
bacteria were titrated to determine the respective library size and colony PCR was conducted 
to calculate the insert rate. Library glycerol stocks were stored at -80°C or directly used for 
scFv-phage production (2.2.3.4). 
2.2.3.4 Production of scFv-phage (packaging) 
In this work, antibody gene libraries were packaged with Hyperphage, which lacks the gene 
gIII for the wild type minor coating protein pIII (Rondot et al. 2001) and therefore only integrates 
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scFv-pIII fusion proteins. This leads to a multivalent scFv-display on each phage, thus 
increasing the chance to select antigen-specific scFv fragments within the first panning round. 
Library packaging was performed as described before (Kügler et al. 2018). In short, culture 
was inoculated from library glycerol stock and infected with a 20-fold excess of Hyperphage. 
Upon incubation overnight, produced phage were precipitated with PEG/NaCl solution, purified 
and resuspended in phage dilution buffer. Phage libraries were titrated to determine the 
respective phage concentration and analysed in SDS-PAGE (2.2.5.1) and immunoblotting 
(2.2.5.3) to confirm the display of scFv-pIII fusion proteins. Phage libraries were aliquoted and 
stored at 4°C.  
2.2.4 Selection of recombinant TIL-B-antibodies 
2.2.4.1 Selection of scFv antibodies in microtiter plates 
The selection of antibody fragments from phage libraries in microtiter plates was conducted as 
described previously (Hust et al. 2014; Russo et al. 2018). Briefly, scFv-phage libraries were 
incubated on the respective immobilised antigen. Whereas unbound phage were removed by 
stringent washing, bound phage were eluted and used for re-infection of bacteria. Upon co-
infection with helper phage M13K07, scFv-phage were amplified overnight and used for the 
next panning round. In this work, antigen-binding phage were enriched over three panning 
rounds. Eluted phage of the last panning round were used for re-infection of bacteria. Single 
clones were picked for production of soluble scFv fragments, which were screened for antigen-
binding in ELISA.  
2.2.4.2 Selection of scFv antibodies on cells 
The selection of scFv-phage libraries on whole cells was performed as described before (Fahr 
and Frenzel 2018). The pharyngeal carcinoma cell line FaDu was used target cell line for 
selection. Prior to selection, phage libraries were depleted on HEK293 and CHO-K1 cells, 
which served as negative cell lines. Upon washing, bound phage were eluted and used for re-
infection of bacteria and phage production. FaDu-binding phage were enriched over three 
panning rounds. Eluted phage of the last panning round were used to re-infect bacteria. Single 
clones were picked for production of soluble scFv fragments, which were screened for FaDu-
binding in flow cytometry. Enrichment of FaDu-binding antibodies was analysed by plotting the 
mean fluorescence intensity (MFI) of each clone on the respective cell line and by calculating 
the variance within the mean values by using the one-way ANOVA test (GraphPad Prism7 
software). P values less than 0.05 were considered statistically significant (*P < 0.05; 




2.2.5 Biochemical and immunological methods 
2.2.5.1 SDS-PAGE 
For separation of proteins by their size, SDS-PAGE was performed. Mini-Protean TGX stain-
free gels (Bio-Rad Laboratories, Munich, Germany) were used according to the instructions 
given by the supplier. For conventional protein samples 12% gels were used whereas eluate 
of immunoprecipitation was separated in 4-15% gradient gels. Protein samples were 
supplemented with 4x Laemmli buffer and 10x DTT and incubated at 95°C for 10 min. 14 µL 
of each sample and 5 µL of the respective protein standard were loaded and SDS-PAGE was 
run at 250 V for 25 min in running buffer. For conventional SDS-PAGE and Coomassie staining 
the Precision Plus Protein Standard unstained (Bio-Rad Laboratories, Munich, Germany) was 
used whereas for Western blotting the Precision Plus Protein Standard all blue (Bio-Rad 
Laboratories, Munich, Germany) was loaded additionally. Upon electrophoresis, gels were 
documented and analysed under UV light or used for Coomassie staining or immunoblotting. 
2.2.5.2 Coomassie staining 
Upon SDS-PAGE, gel was transferred into a glass petri dish and covered with Coomassie 
staining solution. Gel was heated in a microwave for 40 s and incubated at room temperature 
on a rocker for 20 min. Coomassie staining solution was removed and gel was covered with 
10% acetic acid. Gel was heated in a microwave for 40 s and incubated at room temperature 
on a rocker for 1 h. Acetic acid was removed, gel was documented and used for mass 
spectrometric analysis. 
2.2.5.3 Immunoblotting 
Prior to immunoblotting, a PVDF membrane was incubated in 98% ethanol for 2 min whereas 
blotting paper was hydrated in blotting buffer. Blotting paper was placed in a blotting device 
and topped with membrane, the SDS-gel and another blotting paper. Blot was run at 20 V for 
45 min. Upon incubation, blotting paper and gel were discarded and membrane was incubated 
in MPBST for 1 h on a rocker. Blocking solution was discarded and membrane was washed 
three times with PBST. Membrane was incubated in 5 mL primary antibody solution (1 mg/mL 
in MPBST) and incubated for 1 h at room temperature on a rocker. Solution was discarded, 
membrane was washed three times with PBST and incubated in 5 mL HRP-conjugated 
secondary antibody (Merck KGaA, Darmstadt, Germany) diluted 1:1000 in MPBST. Solution 
was discarded and membrane was washed three times in PBST. DAB reagent was prepared 
by adding 200 µL DAB stock and 1 µL 30% hydrogen peroxide to 10 mL DAB reaction buffer. 
Membrane was incubated in DAB reagent at room temperature for 20 min. Reagent was 
removed and collected in a special waste for heavy metals. Membrane was washed three 
times with water, dried between paper towels and documented.  
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2.2.5.4 Titration ELISA (enzyme-linked immunosorbent assay) 
Titration ELISA was used in order to analyse dose-dependent binding of antibody candidates 
to desired antigens. A sufficient number of wells of a 96-well assay plate (Corning, Inc., New 
York, USA) were coated with the appropriate antigen diluted in PBS (2 ng/µL). In parallel, an 
identical number of wells was coated with BSA-PBST as negative control. Plate was incubated 
for 1 h at room temperature or overnight at 4°C. Solution was removed and wells were blocked 
with 300 µL BSA-PBST for 1 h at room temperature on a rocker. Upon incubation, all wells 
were washed 3 times with PBST in an ELISA washer. Starting from a concentration of 
10 µg/mL, primary antibodies were diluted 1:√10 in BSA-PBST and added to the appropriate 
antigen and control wells. Upon incubated for 1 h at room temperature on a rocker wells were 
washed 3 times with PBST in an ELISA washer. HRP-conjugated secondary antibody (Merck 
KGaA, Darmstadt, Germany) was diluted 1:1000 in BSA-PBST and added to each well. Plate 
was incubated for 1 h at room temperature on a rocker and washed subsequently 3 times with 
PBST in an ELISA washer. TMB reagent was prepared freshly before use and added to each 
well. Upon 25 min of incubation at room temperature reaction was stopped by adding 
1N sulfuric acid and plate was documented in an ELISA reader. Absorbance signals were 
normalised and plotted against a logarithmic scale of the respective antibody concentration to 
determine the EC50 value reflecting the half-maximal effective concentration. 
2.2.5.5 Immunoprecipitation  
In order to identify potential targets of antibody candidates, proteins were precipitated from 
whole cell lysate of FaDu or transfected antigen expressing HEK293 cells (2.2.6.9). Lysate 
prepared from non-transfected HEK293 cells was used as negative control. 
Immunoprecipitation was conducted using the SureBreads Protein A Magnetic Beads (Bio-
Rad Laboratories, Munich, Germany) according to the manufacturer’s protocol. Eluted proteins 
were analysed in SDS-PAGE (2.2.5.1) and Coomassie staining (2.2.5.2). Bands, which were 
exclusively present in the eluate of the target cell line but not or less intensely present in the 
control lysate were excised and identified in mass spectrometry. Protein purification from gel, 
mass spectrometric analysis and raw data evaluation were kindly performed by Dr. Roland 
Kellner (Merck KGaA, Darmstadt, Germany). 
2.2.5.6 Immunostaining of mammalian cells 
Cells, which were used for immunostaining were harvested using Versene (EDTA) to preserve 
surface antigens (2.2.6.4) whereas non-adherend HEK293 cells were always obtained freshly 
from current culture. For immunostaining, 2 x105 cells/well were aliquoted into a 96 well plate 
(u-shape, PP) and pelleted by centrifugation (300xg, 4°C, 5 min). Cells were washed once with 
FACS buffer and resuspended in the appropriate primary antibody diluted in FACS buffer. 




with an AlexaFluor647-conjugated secondary antibody (Thermo Fisher Scientific, Dreieich, 
Germany) diluted 1:2000 in FACS buffer. Upon 15 min of incubation of ice protected from light, 
cells were washed twice, resuspended in FACS buffer supplemented with propidium iodide 
(1:10000 of 1% PI) and analysed in a flow cytometer (2.2.5.7).  
2.2.5.7 Flow cytometric analysis of cells 
Forward scatter (FSC) plotted against sideward scatter (SSC) was used to remove cell debris 
and smaller highly granular cells by gating. Within the gated cell population, dead cells (PI+) 
were detected with a 585 ± 42 nm filter (PE-channel). Living cells were gated and plotted in 
forward scatter width (FSC-W) against sideward scatter area (SSC-A) to enable differentiation 
between single cells and doublets. Within the gated subpopulation, GFP and FITC signals 
were detected with a 525 ± 40 nm filter (FITC-channel) whereas APC and Alexa Fluor 647 
signals were detected using a 660 ± 10 nm filter (APC-channel). Analysis and evaluation of 
flow cytometric data was performed using FlowLogic.  
2.2.5.8 Size exclusion chromatography (SEC) 
SEC was used to test if antibody solutions contained monomers, aggregates or degradation 
products. Antibodies were diluted in PBS (200 µg/mL) in a glass micro vial and placed into the 
autosampler of the HPLC system. The Protein Standard Mix 5 – 600 kDa (Merck KGaA, 
Darmstadt, Germany) was used as reference. Defined molecular weight of each component 
of the protein standard mix was plotted against the corresponding detected retention times to 
obtain a standard curve facilitating determination of the molecular weight of the appropriate 
analyte. Curve area represented the respective proportion of each component within the 
sample.    
2.2.5.9 Measurement of antibody affinities 
Kinetics measurement in this work were conducted using biolayer interferometry (BLI) in the 
Octet system (FortéBio, Fremont, USA) according to the manufacturer’s protocol. Antibody 
candidates (human IgG format) were immobilised on anti-human IgG Fc capture (AHC) or on 
anti-human Fab-CH1 (FAB2G) biosensors and exposed to different concentrations of the 
desired antigen diluted in BSA-PBST. Upon loading, association of the respective antigen was 
detected followed by dissociation in BSA-PBST. Upon data acquisition, curves were fit using 
a mathematical model (1:1 interaction, global fit) facilitating calculation of the on-rate (kon) and 
off-rate (kdis) of the respective antibody. The resulting affinity constant Kd (kon/kdis) was 




2.2.6 Cell culture methods 
Each protocol described in this section was performed under sterile conditions using a laminar 
flow bench using sterile consumables, media and solutions. 
2.2.6.1 Thawing of cells 
Frozen cells were thawed in a water bath at 37°C until cells were not thawed completely. Cells 
were transferred into 13 mL of the appropriate culture medium in a 15 mL falcon tube. Cells 
were pelleted by centrifugation at 120xg and room temperature for 5 min. Supernatant was 
discarded, cells were resuspended in 5 mL medium and used for experiments or transferred 
into 15 mL medium in a T75 flask for further culturing. Cells were incubated at 37°C and 
5% CO2 for 48 h.  
2.2.6.2 Subculturing of cells 
FaDu, Detroit-562 and CHO-K1 cells were grown in T75 (or T175) cell culture flasks and 
subcultured every second or third day. Culture medium was removed, cell layer was rinsed 
with 5 mL (or 10 mL) PBS and 2 mL (or 5 mL) trypsin/EDTA were added. Cells were incubated 
at 37°C for 5 – 10 min until cells were detached completely. Trypsin/EDTA was inactivated by 
adding culture medium. An appropriate volume of cells was transferred into a fresh flask and 
topped up to 20 mL (or 40 mL) with medium. Cells were further incubated at 37°C and 5% CO2 
for 48 or 72 h. The respective culture media and splitting ratio is listed in the table below (Table 
20). Culturing of HEK293 cells was performed by Marie Kastull (Yumab GmbH, Braunschweig, 
Germany).  
 
Table 20: Culture media and splitting ratios of used cell lines 
Cell line  Culture medium Splitting ratio 
FaDu DMEM + 10% FBS + 1% Penicillin/Streptomycin 1:3 or 1:4  
Detroit-562 DMEM + 10% FBS + 1% Penicillin/Streptomycin 1:3 or 1:4 
CHO-K1 RPMI 1640 + 10% FBS + 1% Penicillin/Streptomycin 1:6 or 1:10 
 
 
2.2.6.3 Counting of cells 
Prior to counting, cells were stained with Trypan blue to facilitate differentiation of dead and 
living cells. Cells were mixed 1:1 with 0.1% Trypan blue, introduced into a Neubauer chamber 
and living cells were counted under a microscope. Number of counted cells in 4 larger squares 




2.2.6.4 Harvesting cells for experiments 
If needed for experiments, cells were detached using Versene (EDTA) instead of trypsin/EDTA 
in order to preserve surface proteins. Supernatant of a grown T75 (or T175) flask was 
discarded and cells were rinsed with 5 mL (or 10 mL) PBS. For detaching of cells, 2 mL (or 
5 mL) Versene (EDTA) were added and incubated for 10 – 15 min at 37°C until cells were 
detached completely. Cells were rinsed with 8 mL (or 15 mL) culture medium, transferred into 
a falcon tube and counted in a Neubauer chamber (2.2.6.3). Cells were either frozen (2.2.6.5) 
or directly used for experiments.  
2.2.6.5 Freezing of cells 
Cells were harvested using Versene (EDTA) (2.2.6.4) for experiments or trypsin/EDTA 
(2.2.6.2) and counted in a Neubauer chamber (2.2.6.3). Cells were pelleted by centrifugation 
at 120xg and room temperature for 5 min. Supernatant was discarded, cells were resuspended 
in the appropriate volume of freezing medium (Table 21) (4 – 6 x106 cells/mL) and immediately 
aliquoted into 1.8 mL cryo tubes (1 mL/vial). Tubes were incubated in a freezing container filled 
with isopropanol at -80°C for 24 h and transferred into a liquid nitrogen tank for long term 
storage (cell bank) or kept at -80°C for experiments. 
 
Table 21: Composition of freezing media 
Cell line  Freezing medium 
FaDu DMEM + 20% FBS + 10% DMSO 
Detroit-562 DMEM + 20% FBS + 10% DMSO 
CHO-K1 RPMI 1640 + 20% FBS + 10% DMSO 
 
 
2.2.6.6 Antibody production  
Transient transfection of HEK293 cells for antibody production was performed as described 
before (Jäger et al. 2013). For production of human IgG, plasmid DNA of heavy and light chain 
were co-transfected in a ratio of 1:1. Antibodies were purified form culture supernatant using 
the MabSelect Sure Protein A purification system (Merck KGaA, Darmstadt, Germany) 
according to the manufacturer’s protocol. Antibody production and protein purification were 
kindly performed by Marie Kastull and Chantal Lingner (Yumab GmbH, Braunschweig, 
Germany). Purified antibodies were aliquoted and stored at -20°C. 
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2.2.6.7 Transfection of cells for protein surface expression 
In order to obtain target-expressing cells for antibody binding studies, HEK293 cells were 
transfected with plasmid DNA coding for the appropriate antigen-GFP fusion protein as 
described before (Jäger et al. 2013). Two days upon transfection cells were harvested and 
transfection efficacy was determined (2.2.6.8). Cells were counted (2.2.6.3) and either frozen 
(2.2.6.5) or directly used for experiments.  
2.2.6.8 Determination of transfection efficacy 
HEK293 cells were harvested two days upon transfection (2.2.6.7) and 500 µL of the collected 
cell suspension was transferred into a 1.5 mL reaction tube. Cells were pelleted by 
centrifugation (2000 rpm, 5 min, 4°C), washed and resuspended in PBS. Cells were diluted 
1:2 in PBS and analysed in a flow cytometer (2.2.5.7). GFP-expressing cells were quantified 
to determine the transfection efficacy.  
2.2.6.9 Preparation of whole cell lysate 
For preparation of cell lysate, cells were harvested using Versene (EDTA) to preserve integrity 
of surface proteins (2.2.6.4). Non-adherend HEK293 cells were obtained freshly from current 
culture. In total 107 cells were aliquoted in a 15 mL falcon tube and centrifuged at 300xg and 
4°C for 5 min. Supernatant was discarded and cells were washed twice in ice-cold PBS. NP40 
cell lysis buffer was supplemented with 1 mM PMSF and Halt Protease Inhibitor Cocktail 
(Thermo Fisher Scientific, Dreieich, Germany) and cell lysate was prepared according to the 
manufacturer’s protocol. Cell lysate was aliquoted and stored at -80°C or directly used for 


















3.1 Antibody libraries from TIL-B cells 
3.1.1 Processing of tumor samples and isolation of TIL-B cells 
Tumor samples were obtained from head and neck cancer patients who had undergone 
curative surgery within their intended treatment and were kindly provided by Prof. Dr. Andreas 
Gerstner (Städtisches Klinikum Braunschweig, Germany). Tissue of 36 patients was 
processed to obtain a single cell suspension and B cells were quantified by CD19/CD45 co-
staining and flow cytometric analysis. Samples were grouped into “high” (≥1.00%), “moderate” 
(≥0.10%), “low” (≥0.01%) or “not detectable” (<0.01%) according to the amount of detected B 
cells relative to all detected cells (Figure 3).  In 69% (25 out of 36) of all considered samples 
CD19+/CD45+ cells were observed (Figure 4). Besides four samples, which were classified as 
“high” most samples showed “moderate” or “low” B cell amount. In 11 samples less than 0.01% 
B cells were found, which was considered as “not detectable”. Distribution of male and female 
patients was similar in each subgroup (75-91% male) and comparable to the complete sample 
collection (~82% male) (Figure 4). Thus, no obvious correlation of gender and detected B cell 
amount was seen.     
 
 
Figure 3: Division of tumor samples according to detected B cells. Cells from whole tissue single 
cell suspensions were co-stained with anti-CD19 FITC- and anti-CD45 APC-conjugated antibodies and 
analysed in flow cytometry. Amount of double-positive B cells (CD19+/CD45+) was calculated relative 
to all detected events. Samples were grouped into high (≥1.0%), moderate (≥0.1%), low (≥0.01%) and 
not detectable (<0.01%). Exemplary tumor samples (YUHANXXX = patient number) are shown in the 





Figure 4: B cell amount detected in patient-derived tumor samples. Processed samples were 
grouped in “high” (≥1.0%), “moderate” (≥0.1%), “low” (≥0.01%) and “not detectable” (<0.01%) according 
to the B cell amount detected in flow cytometry. Bars indicate the sample count in each group relative 
to all considered samples.  
 
If detectable in flow cytometry, B cells were isolated from whole tissue cell suspension using 
anti-CD19 magnetic beads. The CD19+ cells were lysed, and the lysate was stored in RNA 
preparation buffer for later antibody library construction.  
 
3.1.2 Antibody library construction  
TIL-B-derived scFv-libraries were constructed from seven different tumor samples. Total B cell 
RNA was isolated and used for cDNA synthesis by reverse transcription. Variable antibody 
domains were amplified (both IgG and IgM) and cloned into phagemid pHAL30. The final library 
sizes ranged from 1x107 to 2x108 with insert rates of scFv gene fragments varying between 
79% and 100% (Table 22). No correlation was observed when comparing the library size to 
the appropriate B cell amount within each sample. Samples with higher B cell numbers (e.g. 
YUHAN028) did not result in larger libraries compared to samples with lower B cell numbers 
(e.g. YUHAN007). On the other hand, although B cell counts were below detection level in 
YUHAN009, amplification of antibody genes was still successful (Table 22).  
Within this work, several batches of phage libraries were prepared freshly before use. Here, 
titers were batch-dependent, but they always ranged between 7x1010 – 2x1012 cfu/mL. In 
Western blotting two prominent bands at approximately 90 kDa and 100 kDa were observed 
for all libraries corresponding to the expected size of pIII-scFv-fusion proteins (Figure 5). Given 
the well-known aberrant electromobility shift of pIII and its fusion proteins in SDS-PAGE 
(Goldsmith and Konigsberg 1977), this indicated a sufficient display of scFv-fragments on 




Table 22: Antibody library and sample characteristics 
Library Origin* Gender B cells B cell count** Library size Insert rate 
YUHAN007-κ 
YUHAN007-λ 



















































Figure 5: Packaging of TIL-B libraries. After packaging with Hyperphage, 1010 phage were analysed 
by immunoblotting. pIII-particles were detected using a pIII-specific antibody as primary antibody and 
an HRP-conjugated secondary antibody. M: Precision Plus Protein Standard (all blue).   
 
3.1.3 NGS analysis of antibody libraries and patient data  
In order to obtain an insight into the characteristics of the TIL-B-derived antibody libraries, next 
generation sequencing (NGS) was conducted. Sequencing reactions and raw data processing 
were kindly performed by Dr. Thomas Clarke (EMD Serono, Billerica, USA). Libraries were 
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sequenced in a multiplexed MiSeq run resulting in approximately 2x104 – 8x104 sequences 
each of VH and Vκ/Vλ. Data was cleared form non-overlapping reads and short sequences 
(<375 bp). To address library diversities (NGS), unique antibody domains (VH and Vκ/Vλ) were 
identified based on their combination of CDR3 and V-gene and counted. The unique light and 
heavy chain variable regions (102 to 104 each) were multiplied to estimate the maximal possible 
library diversity (NGS) assuming, that all possible combinations were represented. The 
resulting library diversities ranged from 1.2x105 to 7.8x107 and, thus were covered by the 
library size determined upon transformation (Figure 6). Corresponding to the detected B cell 
amount, the highest library diversities were observed for YUHAN012, YUHAN022 and 
YUHAN028. Both YUHAN009-derived libraries showed the lowest diversity in NGS analysis, 
which correlated with the lowest B cell count but was not consistent with the highest library 
size. Diversity and size of all libraries were lower than the maximal theoretical B cell diversity, 
which was calculated by potentiating the theoretical B cell count derived from the B cell amount 
detected in flow cytometry in relation to the total cell count of the tissue cell suspension. 
 
 
Figure 6: TIL-B library sizes and diversities. Maximal theoretical diversity was calculated based on 
the B cell amount detected in flow cytometry in relation to the total cell count within the tissue cell 
suspension and the random pairing of VH and VL during cloning (B cell count ²). *: For YUHAN009, the 
maximal possible B cell amount below detection level of 0.009% was assumed for calculation. Real 
library size was determined by counting single colonies after transfection in library cloning. Maximal 
possible diversity (NGS) was estimated by multiplication of unique VH and VK/VL observed in NGS 
analysis. 
 
Quantification of antibody sequences according to their origin revealed that all considered 




and YUHAN022 showed a comparable distribution of IgG and IgM but differed considerably in 
B cell number. The same was observed for YUHAN011 and YUHAN028 (Figure 7). Thus, no 
correlation of the IgG proportion with the appropriate B cell numbers detected in the 




Figure 7: Abundance of IgG genes versus B cell count. Bars indicate the amount of B cells detected 
in flow cytometry. *: For YUHAN009, the maximal B cell amount below detection limit of 0.009% was 
assumed. Proportion of IgM and IgG genes in the respective library is shown in the pie charts above.   
 
To analyse the antibody repertoire of the TIL-B cell populations used for the library 
construction, the abundance of all V-gene subfamilies of variable heavy and light chain 
domains were determined based on the NGS data (Figure 8). Comparing the heavy chains of 
both kappa and lambda libraries, a highly similar V-gene abundance was observed within each 
sample as expected regarding the same TIL-B cell source. The overall distribution was similar 
between the considered libraries except for YUHAN007 and YUHAN009, which differed in 
many cases. In average IGHV3 and IGHV4 were the most abundant subfamilies (25-30%) 
followed by IGHV1 representing the third leading group. For YUHAN007 in contrast, a higher 
abundance of IGHV5 and IGHV7 was observed whereas in YUHAN009 the IGHV3 subfamily 
dominated with ~60%. Within the kappa light chains IGKV1 and IGKV4 were the most 
abundant V-genes followed by IGKV4 (Figure 8). As exception, in YUHAN009 the subfamily 
IGKV6 accounted for ~35% of the clones, whereas in the other libraries this subfamily was 
negligibly represented. Except of YUHAN007 and YUHAN009, the V-gene distribution within 
the lambda light chains was mainly dominated by IGLV3 (~40%) followed by IGLV2 and IGLV3, 
which were both represented in similar abundance (Figure 8). Consistently, IGLV3 was most 
abundant in YUHAN009 and accounted for ~70% of all V-genes resulting in an under-
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representation of IGLV1 and IGLV2 compared to the other libraries. In YUHAN007 in contrast, 
IGLV1 was the most abundant subfamily accounting for ~70% of all observed v-genes whereas 
IGLV2 and IGLV3 were evenly distributed (~10%). 
 
 
Figure 8: Distribution of V-genes within TIL-B libraries. Abundance of V-genes within the TIL-B 
libraries was calculated based on NGS data 
 
In summary, NGS analysis revealed good quality of all considered libraries with high diversities 
representing a diverse V-gene repertoire. Thus, libraries were considered as suitable for phage 
display selection.  
 
3.2 Selection of TIL-B-antibodies on cancer-related targets 
To analyse the presence of cancer-related antibodies within the TIL-B-derived libraries, 
selection on a known cancer target was conducted. The matrix metalloproteinase 9 (MMP-9) 




formation and patient survival has been widely described making it a potential prognostic 
marker for various cancer types (Shao et al. 2011; Cho et al. 2003). Investigation of antibody 
responses performed in our laboratory with the patient samples used in this study also detected 
response against MMP-9 (Kilian Zilkens, personal communication) 
 
3.2.1 Panning and screening on MMP-9 
In order to select MMP-9-specific antibodies, phage libraries of all seven donors were pooled 
(kappa and lambda kept separately) and used for panning on immobilised recombinant human 
MMP-9 in microtiter scale. After third panning round, bacteria were re-infected with eluted 
phage for production of soluble scFv fragments. A total of 644 clones were screened (276x 
kappa, 368x lambda) for binding to MMP-9. BSA and skim milk powder served as control 
antigens (Figure 9).  
 
 
Figure 9: Screening for MMP-9-specific antibodies. Soluble scFv-fragments were produced after 
three panning rounds and tested for MMP-9-specific binding in screening-ELISA. scFv-containing 
production supernatants were incubated on immobilised antigen and detected by a myc-tag-specific 
antibody and an HRP-conjugated antibody. Skim milk powder (MP) and BSA were used as control 
antigens. Clones were considered as hits (red dots) if signal to noise ratio (s/n) on both MP and BSA 
were >2 and the absorbance on MMP-9 was >0.1. If clones, which did not meet these thresholds are 
depicted as grey dots.  
 
In total, 148 hits were detected (23% hit rate), which showed binding to MMP-9 but no cross-
reactivity to the two control antigens (Figure 9). From 95 sequenced clones, 19 were identified 
as unique upon sequencing. Analysing the NGS data, these 19 antibodies could be assigned 
to four different patients out of seven (>50%), revealing that MMP-9-specific antibodies 
occurred in several independent patients suffering from head and neck cancer. 
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3.2.2 Characterisation of anti-MMP-9 antibodies     
3.2.2.1 Binding to MMP-9 in ELISA and immunoblotting  
Based on the signals observed in screening, three anti-MMP-9 antibodies were chosen for 
further characterisation and converted to human IgG format. To confirm that binding abilities 
remained unaffected upon format conversion, reactivity was analysed in ELISA (Figure 10).  
 
 
Figure 10: Titration-ELISA on recombinant human MMP-9. Dilution series of the antibodies (human 
IgG) were incubated on immobilised MMP-9 or BSA as control antigen and detected by an HRP-
conjugated secondary antibody. EC50 values were determined upon signal normalisation and amounted 
0.16 nM for Mep040.2_A_H5, 5.03 nM for Mep040.2_A_D2, 0.34 nM for Mep040.2_D_A8 and 0.18 nM 
for the anti-MMP-9 antibody used as positive control. 
 
All antibodies showed a sigmoidal dose-dependent binding curve on human MMP-9 without 
background signals on BSA (Figure 10). The calculated EC50 values varied from 0.16 nM to 
5.03 nM. In immunoblotting, MMP-9 (80 – 90 kDa) was detected using Mep040.2_A_H5 and 
Mep040.2_D_A8 as primary antibodies, whereas no signal was obtained using 
Mep040.2_A_D2 (Figure 11). In case of Mep040.2_A_H5 additional bands (50 – 75 kDa) were 





Figure 11: Immunoblot of MMP-9. Antibodies (human IgG) were used as primary antibodies for 
staining of recombinant human MMP-9 and were detected by an HRP-conjugated secondary antibody. 
M: Precision Plus Protein standard (all blue).   
 
3.2.2.2 Binding to MMP-9-expressing cells 
The selected MMP-9- antibodies were tested in flow cytometry and in immunoprecipitation 
assays. HEK293 cells were transfected with an MMP-9-GFP fusion protein comprising a 
transmembrane domain to ensure surface expression of the target. Two days upon 
transfection cells were harvested and transfection efficacy was determined (52.8% GFP+ 
cells). Cells were stained with MMP-9-specific antibodies, which were detected using a 
fluorochrome-conjugated secondary antibody (APC+). Non-transfected population (GFP-), 
cells transfected with a control antigen or empty vector as well as non-transfected cells were 




Figure 12: Binding to MMP-9-expressing cells in flow cytometry. Antibodies (human IgG) were 
titrated and tested for binding to MMP-9-expressing cells. Bound antibodies were detected by an 
AlexaFluor647-conjugated secondary antibody. Binding to non-transfected cells and to cells transfected 
with a control antigen or empty vector was tested as negative controls. Non-specific human IgG served 
as isotype control.  
 
In flow cytometry only weak binding to MMP-9-expressing cells could be observed for 
Mep040.2_A_H5 (Figure 12). For Mep040.2_A_D2 and Mep040.2_D_A8 strong binding was 
detected on MMP-9-expressing cells (Figure 12). Reaction to all control cell lines was not 
detectable or negligible indicating MMP-9-selective binding. 
 
3.2.2.3 Immunoprecipitation of MMP-9 
To further evaluate target-selectivity of the considered antibodies, immunoprecipitation from 
cell lysate was conducted. Antibodies were bound to magnetic beads and incubated with lysate 
derived either from MMP-9-transfected cells or from non-transfected cells as reference. Bound 
proteins were analysed in SDS-PAGE and selected bands were identified by mass 






Mep040.2_A_H5 precipitated many proteins from both tested lysates indicating a high cross-
reactivity of this antibody if exposed to whole cell lysate (Figure 13). In contrast, three proteins 
were precipitated in high abundance by Mep040.2_A_D2 and Mep040.2_D_A8 from lysate of 
transfected cells but not from the control lysate. These proteins were identified as MMP-9-GFP 
fusion and single MMP-9 by mass spectrometry (Figure 13). Both antibodies co-precipitated 
only few proteins from control lysate indicating low cross-reactivity to tested whole cell lysates 
and thus highly selective binding to MMP-9.  
 
 
Figure 13: Immunoprecipitation from MMP-9-expressing cells. Antibodies (human IgG) were used 
for immunoprecipitation form lysate of MMP-9-trasnfected cells or non-transfected cells as negative 
control. Eluted proteins were analysed in SDS-PAGE and Coomassie staining. Bands were excised for 
mass spectrometric analysis. Red arrows indicate identified proteins. M: Precision Plus Protein Standard 
(unstained). 
 
3.2.2.4 Kinetics assay 
The previous experiments addressed functionality and MMP-9-selectivity of the new antibodies 
using ELISA, flow cytometry and immunoprecipitation. As expected, performance of each 
antibody varied depending on the given assay. To assess the binding characteristics of each 
antibody in more depth, antigen binding kinetics were analysed using biolayer interferometry 
(BLI).  
Antibodies were captured on human-Fab-CH1-specific sensor tips and exposed to different 
concentrations of diluted antigen in solution. Association and dissociation curves were 
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obtained for each antibody (Figure 14). After applying a global fit (1:1 interaction model), 
association (kon) and dissociation constants (kdis) were determined allowing the calculation of 
the equilibrium constant Kd (Table 23). High affinities were observed for Mep040.2_A_D2 and 
Mep040.2_D_A8 with binding constants of Kd = 3.66 nM and Kd = 3.02 nM, respectively. For 
Mep040.2_A_H5 the affinity observed in BLI was 10 times lower compared to the other 
considered antibodies (Table 23). 
 
 
Figure 14: Kinetics assay with MMP-9. Antibodies (human IgG) were immobilised on anti-human Fab-
CH1 biosensors and exposed to different concentrations of diluted MMP-9. Association and dissociated 
curves were detected and a mathematical model (1:1 interaction) was applied for calculation of binding 
parameters. 
 
Table 23: Summary of MMP-9-binding parameters 
Antibody Antigen kon [1/Ms] kdis [1/s] Kd [nM] 
Mep040.2_A_H5 MMP-9 1.13x104 3.06x10-4 27.1 
Mep040.2_A_D2 MMP-9 9.55x104 3.50x10-4 3.66 





In summary, three MMP-9-specific antibodies were isolated from TIL-B libraries. Two of these 
antibodies showed highly affine binding to MMP-9 with low cross-reactivity and were functional 
in different assays comprising ELISA, immunoprecipitation and flow cytometry. Furthermore, 
the discovery of antibodies against a well-described cancer-related protein confirmed the 
presence of cancer-relevant antibodies within the TIL-B libraries.  
 
3.3 Selection of TIL-B-antibodies on cancer cells  
3.3.1 Cell panning and screening on FaDu  
To overcome the limitation to known cancer targets, TIL-B-derived phage libraries were used 
for selection on whole cancer cells to discover cancer-relevant antibodies independent of their 
appropriate target proteins. FaDu is an epithelial cell line, which originates from human 
pharyngeal squamous cell carcinoma (Rangan 1972). Since it is a well-studied model cell line 
for head and neck cancer (Schmidt et al. 2016; J. T. Cohen et al. 2015; Young et al. 2018) it 
was chosen for antibody discovery in this study. 
For panning on cancer cells, TIL-B-derived phage libraries of five donors were pooled, while 
keeping kappa and lambda libraries separately, and panned on FaDu cells. Upon three 
panning rounds, eluted phage were used for re-infection of bacteria and production of soluble 
scFv-fragments. In total, 736 clones were screened (368x kappa and lambda each) by flow 
cytometry for specific cell binding. Antibodies selectively binding to FaDu without showing 
reactivity with CHO-K1 or HEK293 were considered as specific hits. Of 736 screened clones, 
74 hits were isolated (10% hit rate) (Figure 15 A), of which 26 clones (35%) were found to be 
unique in respect of their sequence. The total number of FaDu-binding antibodies upon 
selection was significantly higher compared to the number of CHO-K1- or HEK293-reactive 






Figure 15: Screening for FaDu-specific antibodies. Soluble scFv-fragments were produced after 
three cell panning rounds and tested for FaDu-specific binding in flow cytometry. ScFv-containing 
supernatants were incubated with the respective cells and detected by a myc-tag-specific antibody and 
an AlexaFluor647-conjugated secondary antibody. Binding to HEK293 and CHO-K1 cells was tested for 
negative control. Mean fluorescence intensity (MFI) of each clone was divided by the MFI of the 
detection system (det. sys.) control to obtain signal to noise (s/n) ratios relative to the background signal. 
(A) s/n ratios on negative control cells were calculated by dividing s/n ratios (det. sys.) of FaDu-signals 
by control signals. Clones were considered as hits if s/n ratio on HEK293 and CHO-K1 < 3 (red dots). 
(B) s/n ratios (det. sys.) of each clone on all three cell lines. Mean is indicated by a dotted line and 
variations were calculated using the one-way ANOVA test. Signals on FaDu were significantly increased 
compared to HEK293 and CHO-K1 (****P < 0.0001).    
 
For further investigation, all 26 unique antibodies were converted into the IgG-like scFv-Fc 
format and re-tested for binding to FaDu and the metastatic site derived Detroit-562 cell line 
(Peterson et al. 1971)  in flow cytometry (Figure 16).  
 
 
Figure 16: Cell binding in flow cytometry. Purified scFv-Fc fragments (50 nM) were tested for binding 
to FaDu, Detroit-562 and HEK293 cells. Clone names are shown as abbreviations 
(Mep038.1_MPX_XX). Bound antibodies were detected by an AlexaFluor647-conjugated secondary 
antibody. Median fluorescence intensity (MFI) of each clone relative to the MFI of the detection system 




After format conversion from scFv to scFv-Fc, four candidates showed no 
(Mep038.1_MPA_A3 & Mep038.1_MPA_B8) or no sufficient binding (Mep038.1_MPA_C3 & 
Mep038.1_MPA_D12) to FaDu cells (Figure 16). These clones were excluded from further 
analysis. The remaining 22 antibodies all showed binding to FaDu cells. A total of 12 antibodies 
also bound to Detroit-562 cells, indicating that the appropriate targets were expressed on both 
head and neck cancer cell lines. Binding intensities on Detroit-562 were generally lower 
compared to the signals obtained on FaDu but still well detectable.  
 
3.2.2 Target identification via immunoprecipitation and mass spectrometry  
Selection of FaDu-specific antibodies from TIL-B-derived scFv-phage libraries resulted in 
22 unique candidates binding to FaDu cells but the identity of the recognised antigen was still 
unknown. To identify the respective targets, antibodies were bound to protein-A-coated 
magnetic beads and exposed to cell lysate derived from FaDu or HEK293 as reference. 
Precipitated proteins were eluted and analysed in SDS-PAGE. Bands, which exclusively or 
more intensely occurred within the FaDu-lanes were considered as potential targets and were 
furhter analysed by mass spectrometry (Figure 17). Protein purification from gel, mass 
spectrometric analysis and raw data evaluation were kindly performed by Dr. Roland Kellner 






Figure 17: Immunoprecipitation for target identification. FaDu-binding antibodies (scFv-Fc; mouse 
Fc) were used for immunoprecipitation form FaDu cell lysate or HEK293 cell lysate as reference. Eluted 
proteins were analysed in SDS-PAGE and Coomassie staining. Bands were excised for mass 
spectrometric analysis. Coloured frames indicate the proteins identified by mass spectrometry of the 
respective bands. M: Precision Plus Protein Standard (unstained). 
 
FaDu-selective bands were observed for nine antibodies, which were identified as three 
different proteins by mass spectrometry. This correlated with the highly similar precipitation 
patterns of the appropriate antibodies observed in SDS-PAGE (Figure 17). According to their 
proposed target (integrin-α3β1, CD71 or CD9) antibodies were grouped and compared. 
Sequence analysis revealed that within the integrin-α3β1- and CD9-binding fraction the 
antibodies shared the same V-gene subfamilies and patient origin (Table 24). Sequence 
alignment revealed that although the same V-genes were used the antibodies were still unique 
due to several silent and non-silent point mutations (Figure 18). In total, 16 differing amino 
acids were found within the integrin-α3β1-binders, which were evenly distributed over the 
whole sequence. For the CD9-binders, 21 different amino acids occurred, which were majorly 
located within the variable light chain domain. Some mutations were shared by all antibodies 
(see CDR2 in VL) whereas other differed in the same position indicating that the considered 







Table 24: Sequence analysis of FaDu-binding antibodies 
Antibody Target V-gene VH  
(identity [%]) 






IGHV3-30*18 (96.3) IGLV3-19*01 (90.7) YUHAN012 
Mep038.1_MPB_C9 Integrin-
α3β1 
IGHV3-30*18 (95.4) IGLV3-19*01 (91.8) YUHAN012 
Mep038.1_MPA_A5 CD9 IGHV4-34*01 (97.2) IGLV3-21*01 (91.8) YUHAN008 
Mep038.1_MPB_F1 CD9 IGHV4-34*01 (97.2) IGLV3-21*01 (86.6) YUHAN008 
Mep038.1_MPA_A7 CD9 IGHV4-34*01 (97.2) IGLV3-21*01 (86.6) YUHAN008 
Mep038.1_MPA_C9 CD9 IGHV4-34*01 (98.1) IGLV3-21*01 (91.8) YUHAN008 
Mep038.1_MPA_F11 CD9 IGHV4-34*01 (97.2) IGLV3-21*01 (90.7) YUHAN008 
Mep038.1_MPB_F3 CD71 IGHV3-21*03 (96.3) IGLV6-57*02 (91.1) YUHAN012 




Figure 18: Non-silent mutations in FaDu-binding antibodies. Alignments of anti-integrin-α3β1 and 
anti-CD9 antibodies. Non-silent mutations in the respective sequence region (FR: framework; CDR: 
complementary determining region) are depicted in red. Sequences were compared to germline (ref.) 
derived from public database (IMGT).  
 
3.2.3 Antibody characterisation 
For further characterisation, antibodies were converted to human IgG format. In order to 
exclude potential protein aggregation, antibodies were analysed by size exclusion 
chromatography (SEC). All antibodies showed a prominent peak at a retention time of ~9 min  
(Figure 19), which corresponded to monomeric IgG and amounted 94 – 99% of the samples 
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(Table 25). Only small amounts of degradation products (~9 kDa at ~12 min) and dimers 




Figure 19: SEC of FaDu-binding antibodies. Antibodies (human IgG) were analysed in SEC and 
detected voltage was plotted against the retention time. A defined protein standard was measured as 







Table 25: Summary of SEC analysis 
Antibody Retention time [min] Percentage area  Molecular mass 
Mep038.1_MPA_A1 9.38 95.8% 122.5 kDa 
Mep038.1_MPB_C9 9.45 97.3% 114.3 kDa 
Mep038.1_MPA_A5 9.14  98.4%  148.0 kDa  
Mep038.1_MPA_A7 9.22 97.1% 139.2 kDa 
Mep038.1_MPA_C9 9.18  98.9% 143.7 kDa 
Mep038.1_MPA_F11 9.17 94.6% 145.0 kDa 
Mep038.1_MPB_F1 9.22  97.9%  139.2 kDa  
Mep038.1_MPA_B3 9.07  98.4% 157.6 kDa  
Mep038.1_MPB_F3 9.53  97.1% 107.1 kDa  
 
 
3.2.3.1 Integrin-α3β1-specific antibodies 
3.2.3.1.1 Binding of integrin-α3β1  
Human integrin-α3β1 was identified as target of Mep038.1_MPA_A1 and Mep038.1_MPB_C9 
by immunoprecipitation and mass spectrometry. To confirm these results, binding to 
recombinant human integrin-α3β1 was analysed in ELISA (Figure 20). For both antibodies a 
concentration dependent sigmoidal binding curve was observed on the antigen without 
showing cross-reactivity to BSA. EC50 values were 0.21 nM and 0.31 nM, respectively. 
 
 
Figure 20: Titration-ELISA on recombinant human integrin-α3β1. Dilution series of the antibodies 
(human IgG) were incubated on immobilised integrin-α3β1 or BSA as control antigen and detected by 
an HRP-conjugated secondary antibody. EC50 values were determined to be 0.68 nM for the anti-




Binding of Mep038.1_MPA_A1 and Mep038.1_MPB_C9 was observed to both pharyngeal 
carcinoma cell lines FaDu and Detroit-562 (Figure 16), which indicated relevance of integrin-
α3β1 in head and neck cancer. This assumption is supported by literature describing integrin-
α3β1 to be expressed in various types of cancer (Thul et al. 2017). Therefore, binding of 
Mep038.1_MPA_A1 to different cancer cell lines was analysed (Figure 21). The selected cell 
line panel comprised NCI-H1975 (non-small cell lung cancer), MKN-45 (gastric cancer), A549 
(lung cancer), NCI-H358 (non-small cell lung cancer, metastatic site), U-87-MG (glioblastoma), 
A431 (epidermoid carcinoma) as well as FaDu, Detroit-562 and HEK293 as references. 
Cultivation of cells, immunostaining and flow cytometry were kindly performed by Laura 
Unmuth (Merck KGaA, Darmstadt, Germany).  
 
 
Figure 21: Binding of Mep038.1_MPA_A1 to cancer cell line panel. Different concentrations 
(100 nM, 10 nM, 1 nM) of Mep038.1_MPA_A1 (human IgG) were used as primary antibody for staining 
of different cancer cells. Bound antibodies were detected by an AlexaFluor647-conjugated secondary 
antibody. A non-specific human IgG was used as isotype control.  
 
As observed before Mep038.1_MPA_A1 showed reactivity to FaDu and Detroit-562 and no 
binding to HEK293, which was expected since for the latter no expression of integrin-α3β1 has 
been reported (Thul et al. 2017). Highest signals were observed on U-87-MG and NCI-H358, 
which was consistent with the high expression level of integrin-α3β1 expected for U-87-MG 
(Thul et al. 2017). For A431 and A549 a moderate expression of integrin-α3β1 has been 
described (Thul et al. 2017) correlating with the signals obtained with Mep038.1_MPA_A1. 
NCI-H358 and NCI-H1975 both originated from lung cancer and were bound by the tested 
antibody. Herein, signal intensity on the metastasis-derived cell line NCI-358 was higher. No 
binding was observed on MKN45 cell originating from gastric cancer, however, no information 




Mep038.1_MPA_A1 showed reaction to all tested cancer cell lines derived from lung cancer, 
glioblastoma, epidermoid carcinoma and pharyngeal carcinoma. 
 
3.2.3.1.2 Kinetics measurement   
To further evaluate the binding profile of both integrin-α3β1-binding antibodies, kinetics 
analysis was conducted using BLI. Antibodies were immobilised on anti-human-Fc (AHC) 
sensor tips and exposed to different dilutions of recombinant human integrin-α3β1. Binding 
profiles obtained in BLI were similar to each other (Figure 22). For both antibodies a very high 
on-rate (kon = 105 1/Ms) and off-rate (kdis = 10-2 1/s) were observed (Table 26) resulting in 
overall dissociation constants of 370 nM and 214 nM, respectively. 
 
 
Figure 22: Kinetics assay with integrin-α3β1. Antibodies (human IgG) were immobilised on anti-
human IgG-Fc biosensors and exposed to different concentrations of diluted integrin-α3β1. Association 
and dissociated curves were detected and the mathematical model “1:1 interaction” was applied for the 
calculation of binding parameters. 
 
Table 26: Summary of integrin-α3β1-binding parameters 
Antibody Antigen kon [1/Ms] kdis [1/s] Kd [nM] 
Mep038.1_MPA_A1 Integrin-α3β1 2.38x105 8.79x10-2 370 
Mep038.1_MPA_A1 Integrin-α3β1 2.82x105 6.03x10-2 214 
 
 
In summary of the results described above, two integrin-α3β1-binding antibodies were 
successfully isolated by cell panning, demonstrating the presence of cancer-related antibodies 
within the TIL-B libraries. Both antibodies showed binding to integrin-α3β1 in ELISA, flow 
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cytometry and immunoprecipitation and low cross-reactivity to other components of the tested 
cell lysates. 
 
3.2.3.2 CD9-specific antibodies 
In order to confirm the specificity for CD9 of some of the patient-derived antibodies selected 
by cell panning as identified by immunoprecipitation and mass spectrometry, binding to 
recombinant human CD9 was analysed in ELISA (Figure 23). Except for Mep038.1_MPA_C9, 
which showed binding at the highest concentration, none of the tested antibodies showed 
reactivity (Figure 23). Thus, binding to human CD9 could not be confirmed in ELISA.  
 
 
Figure 23: Titration-ELISA on recombinant human CD9. Dilution series of the antibodies (human 
IgG) were incubated on immobilised CD9 or BSA as control antigen and detected by an HRP-conjugated 
secondary antibody. EC50 values were not determined since no signals were observed.  
 
In order to exclude complications caused by partial denaturation of CD9 upon immobilisation 
in the ELISA setup, CD9-specificity was tested in flow cytometry. HEK293 cells were 
transfected with a CD9-GFP fusion protein and harvested after two days of cultivation. 
Transfection efficacy of ~68% was determined by quantification of GFP-positive cells. Cells 




used as negative controls. Staining of the different cells revealed reaction of all tested 
antibodies to the GFP-positive population of CD9-transfected cells (Figure 24). In contrast to 
the CD9-specific positive control antibody, no cross-reactivity to the negative controls was 
observed indicating CD9-selective binding.  
 
 
Figure 24: Binding to CD9-expressing cells in flow-cytometry. Antibodies (human IgG) were titrated 
and tested for binding to CD9-expressing cells. It has to be noted that due to high signal intensities 
titration of Mep038.1_MPA_A7, Mep038.1_MPB_F1 and the anti-CD9 antibody started at 1 nM whereas 
for the other antibodies a higher concentration of 5 nM was used. Bound antibodies were detected by 
an AlexaFluor647-conjugated secondary antibody. Binding to non-transfected cells and to cells 
transfected with control antigen or empty vector was tested as negative controls. Non-CD9-specific 




In conclusion, five antibodies isolated from TIL-B libraries were shown to bind CD9-expressing 
cells and to precipitate CD9 from whole cell lysate of the pharyngeal carcinoma cell line FaDu. 
Although binding to CD9 in ELISA was not detected for unknown reason, flow cytometric 
analysis confirmed CD9 as their target.  
 
3.2.3.3 CD71-specific antibodies 
Mass spectrometric analysis identified CD71 as target of the remaining two FaDu-binding 
antibodies. In ELISA, binding to recombinant human CD71 protein was confirmed for both 
tested candidates (Figure 25). Mep038.1_MPB_F3 only showed low signals compared to 
Mep038.1_MPA_B3 and the positive control antibody, but still resulted in a comparable EC50 
of 2.66 nM. For Mep038.1_MPA_B3 intense signals developed faster resulting in an expected 
sigmoidal binding curve and an EC50 of 2.11 nM. In Western blotting no staining was observed 
for both tested antibodies (data not shown). 
 
 
Figure 25: Titration-ELISA on recombinant human CD71. Dilution series of the antibodies (human 
IgG) were incubated on immobilised CD71 or BSA as control antigen and detected by an HRP-
conjugated secondary antibody. EC50 values were determined upon signal normalisation and amounted 
2.11 nM for Mep038.1_MPA_B3, 2.66 nM for Mep038.1_MPB_F3 and 0.27 nM for the anti-CD71 
antibody used as positive control. 
 
Binding to CD71-expressing cells was further analysed in flow cytometry. HEK293 cells were 
transfected with a CD71-GFP fusion protein and tested for GFP-expression. After two days, 
42% GFP-positive cells were detected indicating successful transfection and target-expression 
on the cell surface. Cells transfected with a control antigen (GFP-fusion) or empty vector and 
non-transfected cells were used as negative controls. Both tested antibodies bound to the 
GFP-positive population of CD71-transfected cells (Figure 26). Binding to negative controls 




with the ELISA results, signals observed for Mep038.1_MPB_F3 were lower when compared 
to Mep038.1_MPA_B3.   
 
 
Figure 26: Binding to CD71-expressing cells in flow cytometry. Antibodies (human IgG) were 
titrated and tested for binding to CD71-expressing cells. Bound antibodies were detected by an 
AlexaFluor647-conjugated secondary antibody. Binding to non-transfected cells and to cells transfected 
with control antigen or empty vector was tested as negative controls. Non-CD71-specific human IgG 
served as isotype control. 
 
In order to investigate the binding profile of the CD71-specific antibodies, kinetics was 
analysed using BLI. Antibodies were bound to human-Fab-CH1-specific sensor tips and 
exposed to different concentrations of CD71 (Figure 27). For both antibodies, calculated affinity 
constants were very low (Table 27) indicating highly affine binding. Consistent with the results 
obtained in ELISA and flow cytometry, Mep038.1_MPA_B3 again performed better showing a 






Figure 27: Kinetics assay with CD71. Antibodies (human IgG) were immobilised on anti-human Fab-
CH1 biosensors and exposed to different concentrations of diluted CD71. Association and dissociated 
curves were detected and mathematical model (1:1 interaction) was applied for calculation of binding 
parameters. 
 
Table 27: Summary of CD71-binding parameters 
Antibody Antigen kon [1/Ms] kdis [1/s] Kd [nM] 
Mep038.1_MPA_B3 CD71 1.45x105 5.38x10-5 0.37 
Mep038.1_MPB_F3 CD71 4.75x104 2.54x10-4 5.35 
 
 
In summary two CD71-specific antibodies were identified, which were shown to be functional 
in ELISA and flow cytometry. Immunoprecipitation revealed CD71-selective binding with low 
cross-reactivity to other proteins present in whole cell lysates. BLI revealed high affinities in 
the nanomolar and even sub-nanomolar range. The data confirmed the successful selection 












4.1 Antibody libraries from TIL-B cells 
The present study describes the identification of novel cancer-related antibodies from patient-
derived antibody libraries. The antibody repertoire of tumor-infiltrating B lymphocytes (TIL-B) 
was used, which were isolated directly from fresh tumor specimens. The construction of these 
libraries for selection of cancer-specific autoantibodies has already been investigated before 
for various types of cancer. In most of these studies, B cells were obtained from whole blood, 
tumor draining lymph nodes or the tumor itself (Punt et al. 1994; Pavoni et al. 2007; Campa et 
al. 2016; Novinger et al. 2015). Herein, the isolation of B cells from the tumor core or its 
microenvironment was mainly done by laser capture microdissection (LCD) (P. M. O’Brien et 
al. 2005; Simsa et al. 2005), whereas in the present study B cells were isolated from freshly 
prepared tumor tissue cell suspensions. This procedure facilitated the isolation of larger 
numbers of cancer-associated B cells including a broad variety of B cell subsets. In contrast, 
LCD only allows the isolation of small cell populations from frozen or formalin-fixed paraffin 
embedded (FFPE) tissue sections, which may not reflect the complexity of the complete tumor 
immune environment (Almeida et al. 2015; Espina et al. 2007). Furthermore, LCD suffers from 
low yields of cells, poor cell viability and potential DNA- and RNA-damage caused by tissue 
preparation and the applied laser (Hu et al. 2016). Moreover, the isolation of B cells from freshly 
prepared single cell suspensions enabled the usage of the tumor cells as by-product for 
additional investigations and thus, a more efficient usage of the valuable patient-derived 
material.  
For first proof-of-concept studies, B cells isolated from tumor tissue of seven donors were 
selected for the construction of antibody libraries. Besides three samples with the highest and 
three samples with a moderate B cell amount, one sample was also included with a B cell 
count below detection level (YUHAN009, <0.01%), but which still allowed the amplification of 
antibody genes with PCR. Interestingly, the resulting library size of YUHAN009 was 10 times 
larger compared to e.g. YUHAN011, in which a moderate B cell count was found. This 
observation demonstrates, that probably due to PCR amplification, there was no obvious 
correlation between library size and underlying B cell count. The maximal theoretical library 
diversity including all combinations of VH and Vκ/Vλ of all isolated B cells can be calculated 
based on the theoretical B cell count to the second power and was much higher (107 to 1012) 
than the size of the generated antibody libraries. Besides experimental limitations due to tissue 
processing, RNA isolation, cDNA reverse transcription and PCR amplification, the generation 
of libraries with a diversity of 1012 is extremely time consuming and therefore not feasible for 
patient-derived libraries. Nevertheless, it can be assumed that cancer-associated B cell clones, 
which actively infiltrated the tumor and proliferated there are covered in their paired 
combination in the generated antibody libraries. To access the actual library diversity, NGS 
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analysis was conducted. Analysing the real diversity of a scFv antibody library by deep 
sequencing requires long reads covering the complete scFv (up to 750 bp) and a read depth 
of more than one complete MiSeq run (108 reads) for each library (Glanville et al. 2015), which 
was not possible in the present study. Instead, all TIL-B libraries were analysed in a multiplexed 
MiSeq run, which resulted in 104 to 105 reads each for the VH and the Vκ/Vλ, from which 102 
to 104 sequences were found to be unique (suppl. Table 1). To estimate the maximal possible 
diversity, the unique VH and Vκ/Vλ sequences found in the respective library were multiplied. 
The resulting diversities (NGS) correlated with the underlying B cell count in lower infiltrated 
samples but did not further improve in libraries derived from patient samples with a higher B 
cell count reaching a plateau at a combinatory antibody diversity of ~107. This diversity plateau 
actually meets the typical size of immune libraries (Kramer et al. 2005) caused by clonal 
enrichment within the patient. On the other hand, the obtained read depth of ~104 sequences 
per sample only allowed a maximal detectable diversity of 108 to 1010. This means, that libraries 
from samples with low B cell infiltrate are completely covered by NGS, whereas for libraries 
from samples with high B cell count, such as YUHAN022 and YUHAN028 the risk of unseen 
clones is increased (suppl. Table 1). Nevertheless, the diversities calculated from the 
multiplexed MiSeq data represent a good estimation, which probably is very accurate for most 
of the generated TIL-B libraries with low or moderate B cell infiltration and reveals that they 
are covered by library size. In turn, the YUHAN022- and YUHAN028-derived libraries with high 
B cell infiltration may not contain every possible heavy and light chain combination.  
Analysing the relation of IgG and IgM genes within the TIL-B libraries, no obvious correlation 
with the B cell infiltration was observed. If clonality increases due to clonal expansion in 
samples with higher B cell count as suggested for YUHAN022 and YUHAN028, IgG class 
switch should be expected more often, which should result in a higher amount of IgG genes. 
However, this effect was not observed for all TIL-B libraries. In non-small cell lung cancer 
(NSCLC), the B cell distribution has been reported to be similar between distant non-tumoral 
and tumor tissue but different to peripheral blood, in which the proportion of naïve B cells (IgM) 
was significantly increased (~30% in blood and ~10% in NSCLC) (Germain et al. 2014). 
Consistent with these findings, all TIL-B libraries generated in this study were clearly 
dominated by IgG genes. However, the amount of IgM genes in some libraries was more 
similar to that observed in blood (Germain et al. 2014) indicating, that the higher amount of 
IgM genes may derive from naïve B cells passing through tumor-related blood vessels. Due to 
the isolation of B cells from whole tissue cell suspensions, the B cell subpopulations and their 
localisation in the tumor were unknown, which does not allow comparison of different libraries 




In further investigations the abundance of used V-genes within the TIL-B libraries observed in 
NGS was analysed. In order to outline a potentially altered V-gene usage, all TIL-B libraries 
can be compared to the V-gene distribution described for naïve phage display libraries (Kügler 
et al. 2015) and the in vivo repertoire (Tiller et al. 2013). YUHAN007 and YUHAN009, which 
had the lowest B cell infiltration and the lowest diversity estimated by NGS, differed in many 
characteristics compared to both, the published data and the other TIL-B libraries. Thus, the 
IGHV1 subfamily was observed less frequently whereas a higher abundance of IGHV3, IGHV5 
and IGHV7 was observed. Interestingly, such an overrepresentation of IGHV5 has also been 
described for the repertoire of TIL-Bs and germinal center B cells derived from ductal breast 
carcinoma patients (Nzula et al. 2003) and patients suffering from systemic lupus 
erythematosus (Fraser et al. 2003). Consistent with the observation for YUHAN007 and 
YUHAN009, Fraser and colleagues additionally described a reduction of IGHV1 genes (Fraser 
et al. 2003). Excluding YUHAN007 and YUHAN009, the remaining TIL-B libraries showed a 
similar V-gene distribution among each other. However, the abundance of some subfamilies 
was altered compared to the published data. Within the light chain genes, IGLV3 was 
increased compared to both the naïve libraries and the in vivo repertoire (Kügler et al. 2015; 
Tiller et al. 2013). Although it has been described to be rare, subfamily IGHV2 was increased 
in most libraries similar to the observations published for the repertoire of TIL-Bs derived from 
breast carcinoma patients (Nzula et al. 2003). Additionally, the IGHV4 subfamily was more 
abundant than expected regarding the naïve libraries, whereas the normally frequent subfamily 
IGHV3 was considerably reduced. This also has been described for TIL-Bs in breast and 
cervical cancer (Nzula et al. 2003; P. O’Brien et al. 2001). Although comparable data is scarce 
and patient numbers considered in the present study are low, this data indicates an altered V-
gene distribution within the TIL-B repertoire, which correlates with the reported suspicion of a 
preferential usage of specific subfamilies within a disease context. However, in the current 
stage of our and published research, the underlying mechanism, why and how V-gene 
subfamilies are preferred in TIL-B cells from head and neck tumors is not understood.  
 
4.2 Selection of TIL-B-antibodies on cancer-related targets 
The previous paragraph described that TIL-B libraries from head and neck tumor patients show 
some distinctive characteristics, which make them peculiar compared to the normal antibody 
repertoire in the peripheral blood. To further investigate the presence of cancer-related 
antibodies within the TIL-B libraries, selection on a known cancer target was conducted. The 
matrix metalloproteinase 9 (MMP-9) is a zinc-dependent endopeptidase, which is further 
categorised into the gelatinase subgroup of the MMP-family (Huang 2018). Parallel 
investigations in this research group analysing the antibody response of the same patients to 
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tumor cell material, identified MMP-9 as potential target of antibodies from TIL-B cells (Kilian 
Zilkens, personal communication). This finding was underpinned by literature describing MMP-
9 as prognostic marker for different types of cancer, since its expression and activity was 
upregulated in tumor cells and correlated with tumor stage, vessel invasion, increased 
frequency of metastases and poor survival rates (Shao et al. 2011; Cho et al. 2003). These 
pro-tumorigenic effects of MMP-9 are believed to be mainly caused by its ability to degrade 
the extracellular matrix (ECM), which leads to increased tumor invasion and facilitates 
metastasis formation (Zeng et al. 1999; Kurahara et al. 1999).  
In the present study, 19 unique anti-MMP-9 antibodies were isolated from patient-based TIL-
B libraries. Analysing the NGS data, it was observed that these antibodies originated from four 
different libraries revealing, that antibodies targeting MMP-9 were present in >50% of seven 
head and neck cancer patients. Interestingly, MMP-9 has been described to be important in 
different head and neck cancers including laryngeal carcinoma (Bogusiewicz et al. 2003) and 
oral carcinoma, in which it was only active within the tumor but not in the surrounding stroma 
(Kato et al. 2005). Furthermore, Ruokolainen and colleagues reported, that MMP-9 is 
expressed in >80% of HNSCC and correlates with more aggressive relapse and shortened 
survival (Ruokolainen 2004). These findings outline the important role of MMP-9 in head and 
neck cancer and may explain the presence of anti-MMP-9 antibodies in the majority of patients 
in this study. In the past, therapeutic inhibition of MMPs was studied but long suffered from 
dose-limiting side-effects caused by unspecific targeting of various members of the MMP-
family. However, more recently it experiences a revival with novel, more specific MMP-
inhibitors undergoing clinical trials (Fields 2019). Among them is a humanised antibody, which 
has been shown to reduce primary tumor growth in a mouse model of colorectal carcinoma 
(Marshall et al. 2015). Consistently, Juric and colleagues reported the development of a 
monoclonal anti-MMP-9 antibody, which reduced tumor growth in breast cancer in combination 
with an anti-PD-L1 antibody (Juric et al. 2018). These findings outline the vast potential of 
MMP-9-specific antibodies in cancer therapy and the crucial need of highly specific MMP-9-
inhibitors. The best three candidates out of the 19 MMP-9-binding antibodies isolated from TIL-
Bs were further characterised and showed different binding characteristics depending on the 
applications. Whereas the performance of clone Mep040.2_A_H5 in flow cytometry and 
immunoprecipitation was poor, this clone was highly reactive in ELISA and immunoblotting. 
This data suggests a linear, consecutive epitope, which probably was not well accessible on 
soluble, natively folded MMP-9. Furthermore, this clone showed cross-reactivity to additional 
proteins of the cell lysates probably making it inappropriate for therapeutic application. In 
contrast to Mep040.2_A_H5, the other two clones successfully bound to MMP-9 in ELISA and 
on cells but not or weakly in immunoblotting indicating a conformational epitope. Affinities of 




and cross-reactivity to other cell lysate components was negligible. This indicates MMP-9-
selective binding and makes them suitable candidates for further investigations. In future 
experiments, these antibodies should be tested in immunohistochemistry to exclude binding 
to non-tumoral human tissue. Furthermore, it should be investigated if binding of the antibodies 
affects the enzymatic activity of MMP-9 to estimate their applicability in therapeutic strategies.   
In summary, the selection of TIL-B libraries on MMP-9 provided highly affine anti-MMP-9 
antibodies. This finding demonstrated the presence of cancer-related antibodies within the TIL-
B libraries and created the link between the TIL-B repertoire and the corresponding antibody 
response to tumor antigens, which is investigated in parallel in our research group (Kilian 
Zilkens, personal communication). Moreover, the isolation of anti-MMP-9 antibodies from four 
different patient-derived libraries underlines the relevance of MMP-9 as tumor target in head 
and neck cancer. 
4.3 Selection of TIL-B-antibodies on cancer cells 
The successful isolation of anti-MMP-9 antibodies demonstrated that TIL-B-derived libraries 
contain cancer-related antibodies. Although the discovery of antibodies targeting well-defined 
proteins provides insights into potential anti-tumor reactions, selection against large target 
panels is time consuming and fails to deliver novel non-described target candidates. To 
overcome this limitation, the discovery of antibodies was refocused on cancer cells followed 
by subsequent identification of their unknown targets. The suggestion to use patient-derived 
libraries as source of tumor-specific antibodies has been described before using different 
approaches. Thus, selections have been performed on autologous target panels and cancer 
cell lines (Pavoni et al. 2007; Punt et al. 1994) or on tumor cell lysates (Novinger et al. 2015; 
Campa et al. 2016; Imahayashi et al. 2000) obtaining the B cells either from peripheral blood, 
draining lymph nodes or tumor tissue. Currently, various studies are available concerning 
different types of cancer such as breast cancer, colorectal carcinoma and lung cancer 
(Reuschenbach et al. 2009). However, for head and neck cancer published investigations are 
still rare. Cancers of the head and neck often exhibit immunosuppressive characteristics 
comprising tumor cell modulation as part of immune escape and the recruitment of tumor-
promoting cells, which raises the suspicion that infiltrated immune cells may have a tumor-
supportive function rather than acting anti-tumorigenic (Tong et al. 2012). Recently, Lechner 
and colleagues reported a comprehensive analysis of different B cell subsets in head and neck 
cancer, which revealed an increased number of plasma cells and serum reactivity to tumor-
associated antigens indicating that a humoral anti-tumor response may be initiated in head 
and neck cancer patients (Lechner et al. 2019). In the present study, patient-based antibody 
libraries were selected on cancer cells, which is to our knowledge for the first time described 
for antibody repertoires of TIL-B cells derived from head and neck cancer. A total of 22 unique 
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antibodies were isolated, which bound to the pharyngeal carcinoma cell line FaDu but not to 
the non-cancerous HEK293 or CHO-K1 control cells. For nine antibodies, immunoprecipitation 
and mass spectrometry identified integrin-α3β1, CD9 and CD71 as their respective targets, 
which all are well-described cancer-related proteins. 
Integrins are a large family of heterodimeric surface receptors, which interact with proteins of 
the ECM to mediate adhesion (Hynes 1987; Humphries 2000). In total, there are 19 alpha and 
8 beta subunits known to assemble into 24 different heterodimers, which are further grouped 
according to their ligands (Barczyk et al. 2010). Integrin-α3β1 herein belongs to the laminin-
binding subgroup. In addition to their role in cell adhesion, integrins function as bidirectional 
signalling molecules mediating proliferation, apoptosis, polarity, motility and differentiation by 
transducing extracellular signals (outside-in). On the other hand, they are sensitive to 
intracellular signalling, which promotes their activation resulting in a conformational change of 
both extracellular domains and an altered reaction to agonists and antagonists (inside-out) 
(Hynes 2002; Tolomelli et al. 2017). Additionally, their interaction with different proteins of the 
ECM such as other integrins, cadherins, growth factor receptors and MMPs has been 
described to influence tumorigenesis and metastasis formation in cancer (Tolomelli et al. 2017; 
Roggiani et al. 2016). This may be caused by integrin-dependent adhesion mediating the 
arrest of invading tumor cells at distant organs within the metastatic cascade (Sökeland and 
Schumacher 2019). Due to these pivotal characteristics, most integrins (19 out of 24) have 
been already traded as potential therapeutic targets (Raab-Westphal et al. 2017). However, 
the laminin-binding integrins such as integrin-α3β1 have not been of particular interest so far, 
as their role in tumor progression is controversial and depends on the individual tumor type 
and stage (Raab-Westphal et al. 2017; Ramovs et al. 2017). Nevertheless, there are studies, 
which outline the beneficial aspects of integrin-α3β1 targeting. Kurokawa and colleagues for 
instance suggested integrin-α3 as reliable biomarker for cervical lymph node metastases in 
tongue squamous cell carcinoma (Kurokawa et al. 2008). Furthermore it has been found, that 
expression levels of integrin-α3 are correlates with poor overall survival in head and neck 
squamous cell carcinoma (HNSSC) and that integrin-α3-knockdown leads to reduced cell 
migration and invasion of a HNSCC cell line (Koshizuka et al. 2017). Consistently, Lusche and 
colleagues described that blocking of integrin-α3β1 inhibits aggregation within tumor spheroid 
formation in vitro (Lusche et al. 2019). Consequently, the isolation of anti-integrin-α3β1 
antibodies form patient-derived TIL-B libraries was an interesting finding, which supported the 
assumption that the isolated antibodies may be part of an anti-tumor immune response. The 
selected antibodies bound to integrin-α3β1 in ELISA, flow cytometry and immunoprecipitation. 
Cross-reactivity to other components of the tested whole cell lysates was low indicating specific 
binding. BLI measurement revealed a high on-rate but also a high off-rate. In consequence, 




unexpected regarding the good performance of the antibodies in the other assays. In ELISA, 
the observed binding is usually affected by avidity effects due to dense immobilisation of the 
antigen, which leads to apparently stronger binding, whereas in the used BLI measurement 
setting the antibody is captured first leading to a 1:1 interaction. However, even considering a 
particularly strong avidity effect, in this case the Kd was 1000-times higher than the calculated 
EC50 in ELISA, which was unusual. In SEC, 95-97% monomers were observed for the 
considered antibodies indicating that protein multimer formation or aggregation did not affect 
the BLI assays. Interestingly, integrins have been described to exist in different conformations 
depending on their state of activation (Figure 28). The resting conformation is referred to as 
“bent” since the extracellular domains of both α- and β-chain are folded over, whereas in the 
extended state both chains are straight and either bound to a ligand (extended-open) or free 
(extended-closed) (Tolomelli et al. 2017; Campbell and Humphries 2011). Humphries 
proposed that clustering of integrins and conformational changes upon excitation creates novel 
binding sites for antibodies, which consequently distinguish between integrins according to 
their activation and ligand binding state (Humphries 2004).  
 
 
Figure 28: Three conformational states of integrins (Tolomelli et al. 2017) 
 
The epitope of the integrin-α3β1-binding antibodies in this study is still unknown but since the 
antibodies did not bind in immunoblotting (data not shown) a conformational, potentially non-
consecutive epitope is likely. Regarding the good performance of the antibodies on cells in 
flow cytometry and on cell lysates in immunoprecipitation, it is possible that the appropriate 
antibody binding site may only be accessible in the extended conformation, which may be only 
present in a cellular context. In ELISA in turn, partial denaturation of the antigen during 
immobilisation may have led to unfolding of “bent” integrin, thus revealing the epitope of the 
antibodies. In BLI in contrast, the recombinant integrin was in solution and thus the epitope 
was maybe not accessible or conformationally different due to the “bent” state. The different 
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states of the same antigen and the bivalent avidity effect can explain, why the same antibodies 
are binding to cell-associated and immobilised integrin, whereas binding to soluble 
recombinant protein was poor in BLI. Further investigations including inversion of the assay 
setup (immobilised antigen) and the implementation of different technologies such as surface 
plasmon resonance (SPR) (Homola et al. 1999) or kinetic exclusion assay (KinExA) (Darling 
and Brault 2004) for affinity determination on cells might be helpful to reliably estimate the 
actual affinity. Identification of the minimal epitope for instance by using peptide arrays 
(Lawson et al. 2019) or the ORFeome phage display technology (Fühner et al. 2018) may also 
be useful to further access and assign the antibody binding site and to investigate if it is indeed 
covered within the “bent” conformation. Furthermore, the antibodies should be tested in 
bioassays to investigate their functional effects, for instance by analysing their abilities to block 
integrin-α3β1 signalling or ligand binding, which may lead to the inhibition of cancer cell 
aggregation or motility (Lusche et al. 2019). 
In addition to the anti-integrin-α3β1 antibodies, CD9-binding antibodies were identified upon 
selection on cancer cells. As a member of the tetraspanin superfamily, CD9 is a widely 
expressed transmembrane protein consisting of four transmembrane domains, two 
extracellular loops and an intracellular terminus (Boucheix and Rubinstein 2001; Brosseau et 
al. 2018; Maecker et al. 1997). Besides the interaction with other membrane proteins, 
tetraspanins are known to associate with each other to form so-called tetraspanin-enriched 
microdomains (TEMs), which influence various cellular processes such as cell adhesion, 
motility, growth, differentiation and signal transduction (Brosseau et al. 2018; Hemler 2014; 
Charrin et al. 2014; Hemler 2003). The role of CD9 in cancer is controversial because 
correlations with both tumor suppression (Higashiyama et al. 1995; Copeland et al. 2013) and 
poor prognosis for the patients (Rappa et al. 2015) have been reported. These contrasting 
effects are believed to be dependent on the different interaction partners of CD9, which vary 
according to the given cellular context (Hemler 2014). Association with the prostaglandin F2 
receptor negative regulator (PTGFRN) for instance, has been described to correlate with a 
tumor-promoting effect in glioblastoma, whereas association with EWI-2 in contrast inhibited 
tumor growth (Kolesnikova et al. 2009). Interestingly, in the present study PTGFRN was 
identified as a co-precipitate of CD9 in immunoprecipitation from FaDu cell lysate (faint band 
at ~130 kDa) demonstrating their interaction in the considered cell line. In addition, association 
of tetraspanins with laminin-binding integrins such as integrin-α3β1 has been reported and 
suggestions were made, that this interaction may be the reason why their signalling pathways 
differ from those mediated by other integrins (Stipp 2010). Within the tetraspanin complex, the 
integrin-α3 subunit is directly connected to CD151, which links it to CD9 and CD81 (Yauch et 
al. 1998; Stipp 2010). Association with the TEM-complex in turn regulates integrin-dependent 




complexity of their interactions with different proteins and their functional role in diverse 
biological processes seem to cause the controversial effects of both CD9 and integrin-α3β1 in 
a disease context, which makes them interesting targets for therapy and diagnostics (Vences-
Catalán and Levy 2018; Rappa et al. 2015; Gustafson-Wagner and Stipp 2013).  
In the present study, five CD9-binding antibodies were isolated from TIL-B libraries. Although 
no binding to immobilised CD9 in ELISA could be observed, the antibodies were shown to bind 
to CD9-expressing cells confirming the results obtained from immunoprecipitation and mass 
spectrometry. We assume, that denaturation of the multi-pass transmembrane protein CD9 
during immobilisation in ELISA or recombinant production lead to the destruction of the 
epitopes. Furthermore, since CD9 is strongly associated with other membrane proteins, it is 
possible that conformational epitopes are only formed upon interaction with certain partners 
(e.g. PTGFRN, which was co-precipitated) and hence, are present on CD9-expressing cells 
but not on purified CD9. Consequently, affinity measurement by BLI was not possible, but 
immunoprecipitation of CD9 from cell lysate indicates highly affine binding of the antibodies 
isolated from the TIL-B libraries. Interestingly, the sequences of the five isolated CD9-binding 
antibodies were all based on the same V-gene recombination and shared most of the CDRs 
but were still unique due to various point mutations. Many of these mutations were identical in 
all clones, whereas some of them differed in one or the other position indicating the same 
clonal origin. For Mep038.1_MPA_A7 and Mep038.1_MPB_F1 the most amino acid 
exchanges were found compared to germline. Interestingly, for these two clones also the 
highest signal intensities in flow cytometry were observed indicating, that the number of point 
mutations correlated with stronger binding. This observation raises the suspicion, that the 
isolated antibodies may be affinity matured as consequence of an anti-tumor immune response 
within the patient and may represent different stages of maturation. Similar observations 
referring to increased mutation rates within the CDRs and a decreased germline identity (GI) 
have been reported previously for patient-derived antibodies in different types of cancer 
(DeFalco et al. 2018; Novinger et al. 2015). The overall GI of the isolated CD9-antibodies 
ranged between 90% and 98%, which is similar to affinity-matured antibodies (Hansen et al. 
2002; Gellrich et al. 1999; O’Brien et al. 2001) and consistent with the observation, that these 
antibodies originated from IgG (at least the HC). 
The five anti-CD9 antibodies among each other as well as the two anti-integrin-α3β1 antibodies 
showed the same VDJ and VJ recombination and a CDR3-identity of >85% as reported for 
clonally related antibodies (Rajewsky 1996; Tipton et al. 2015). Somatic hypermutations have 
been described to be characterised by increased rates of non-silent mutations (amino acid 
exchanges) in CDRs compared to framework regions (FR) (Rajewsky 1996; Nzula et al. 2003; 
Hansen et al. 2002). Indeed, high rates of non-silent mutations were also observed in the 
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FaDu-binding antibodies, even if mutations within the first 8 amino acids were excluded, 
because they may be artificially generated by the degenerated PCR primer. For the anti-CD9 
antibodies, mutation rates in general were lower within the heavy chain (1 – 4% in CDR versus 
0.42% in FR), whereas the light chain was more frequently mutated (10-13% in CDRs versus 
1-6% in FR). The observed mutation rates are comparable to somatically hypermutated 
antibodies observed in ductal breast carcinoma patients (Hansen et al. 2002) and in germinal 
center B cells upon antigen stimulation (Kuraoka et al. 2016). Analysing the utilised V-genes, 
it was found that all FaDu-binding antibodies comprised gene subfamilies, which have been 
previously described in an antigen-dependent context. Thus, IGHV3-30, IGHV1-18, IGHV3-
21, IGHV6-57 and IGHV1-51 have been reported to be either enriched upon target selection 
of naïve antibody phage display libraries (Kügler et al. 2015) or even within tumors and draining 
lymph nodes of breast cancer patients (Novinger et al. 2015). Moreover, subfamily IGHV4-34 
has been described to play an important role in autoimmune activity and has been 
predominantly found in autoreactive systemic lupus erythematosus (Tipton et al. 2015). 
Although, it remains to be proven if the FaDu-binding antibodies really contributed to anti-tumor 
immunity or if they are just expressed from bystander TIL-B cells attracted by cytokines in the 
tumor microenvironment (Reuschenbach et al. 2009; Yuen et al. 2016), these findings strongly 
indicate clonal relation and somatic hypermutation of the isolated antibodies. Targeting CD9 
with the TIL-B-derived antibodies consequently may be a promising strategy in cancer therapy. 
Thus, it already has been shown, that silencing of CD9 and its interaction partner CD81 
strongly impaired integrin-α3β1-dependent directed motility of breast cancer cells (Gustafson-
Wagner and Stipp 2013). Additionally, Rappa and colleagues reported, that a monoclonal anti-
CD9 antibody inhibited the metastatic capacity of breast cancer cells and decreased tumor 
growth in mice (Rappa et al. 2015). Interestingly, CD9 is not only expressed on cells but also 
present on the surface of most cancer-associated exosomes, which are extracellular vesicles 
mediating cell-to-cell communication and metastasis formation (Yoshioka et al. 2013). 
Targeting CD9 with antibodies in turn lead to the elimination of cancer-associated exosomes 
by macrophages, which efficiently reduced metastasis formation (Nishida-Aoki et al. 2017). In 
summary, these findings provide evidence, that the anti-CD9 antibodies isolated from TIL-B 
libraries could have play an important role within the tumor microenvironment and therefore, 
may find broad application in cancer therapy. Consequently, CD9 as target and antibodies 
targeting this tetraspanin and its pathways should be further investigated. 
In addition to integrin-α3β1 and CD9, the transferrin receptor 1 (CD71) was identified as target 
of the remaining considered FaDu-binding antibodies. CD71 is a type II transmembrane 
glycoprotein, which prevails as homodimer consisting of two monomers connected by two 
disulfide bonds (Jing and Trowbridge 1987). Through internalisation upon binding of iron-




metabolism, respiration and as co-factor for DNA synthesis (Daniels et al. 2006; Neckers and 
Trepel 1986). Since it is crucial for cell survival and growth, CD71 is ubiquitously expressed in 
low levels on most normal cells, whereas its expression is massively increased in rapidly 
proliferating cells such as epidermal cells and activated PBMCs (Daniels et al. 2006; 
Shindelman et al. 1981). This is consistent with the observations made while characterising 
the two anti-CD71 antibodies isolated from the TIL-B libraries. In immunoprecipitation, CD71-
corresponding bands were also visible in the control lysate but in notably lower concentration 
compared to the FaDu lysate. Consistently, weak binding to all control cell lines was observed 
in flow cytometry, which was also present using the commercial anti-CD71 control antibody. 
Additionally, expression of low levels of CD71 has been described for HEK293, which was 
used for transfection and as control cell line (Thul et al. 2017). This indicated, that the observed 
binding of the antibodies to the control cells and lysates was caused by ubiquitous expression 
of CD71 rather than by cross-reactivity to other antigens. Since CD71 has been reported to be 
upregulated in various types of cancer such as esophageal squamous cell carcinoma (Chan 
et al. 2014), pancreatic cancer (Ryschich et al. 2004) and breast cancer (Shindelman et al. 
1981; Habashy et al. 2010), CD71 has been already traded as potential target for cancer 
therapy. In the past decade, various strategies have been reported to affect CD71 function for 
instance through direct blocking of Tf-binding, inhibition of receptor internalisation or recycling 
and by using the internalising CD71 for the delivery of therapeutic agents (Daniels-Wells and 
Penichet 2016; Luria-Pérez et al. 2016). Although targeting a ubiquitously expressed protein 
is challenging due to undesired side-effects, a number of publications reported promising 
results with one therapeutic agent currently undergoing clinical trials (Luria-Pérez et al. 2016). 
The CD71-binding antibodies selected in this study showed reactivity to both the immobilised 
recombinant CD71 in ELISA as well as to CD71-expressing cells in flow cytometry. In both 
assays, clone Mep038.1_MPA_B3 delivered higher signal intensities compared to 
Mep038.1_MPB_F3. In kinetic measurement, very low Kd values of 0.37 nM and 5.35 nM were 
obtained, which indicated high affinities and correlated with the good performance in 
immunoprecipitation and immunostaining in flow cytometry. Compared to the EC50 
determined in ELISA, the obtained Kd values were even lower than expected. In our research 
group, it has been observed previously, that antibodies binding to immobilised CD71 in ELISA 
may not always bind to soluble CD71 and vice versa, which indicates, that CD71 
conformationally changes upon immobilisation and potentially explains the observed weaker 
binding in ELISA (Thomas Schirrmann, personal communication). Nevertheless, both tested 
antibodies showed high affinities to soluble CD71 and negligible cross-reactivity to other 
components of the tested cell lysates, which makes them interesting candidates for future 
investigations estimating their applicability in cancer therapy.  
80 
 
In summary, the present study describes the selection of affine antibodies against the four 
cancer-related proteins MMP-9, integrin-α3β1, CD9 and CD71. To our knowledge this is the 
first identification of potential target proteins using the TIL-B antibody repertoire of head and 
neck cancer patients. The isolated antibodies bound their respective targets with high affinities 
in different assays comprising ELISA, flow cytometry, immunoprecipitation and BLI. The 
identification of clonally related, somatically hypermutated antibodies against well-described 
cancer-associated proteins and the predominant isolation of selection-associated V-gene 
subfamilies strongly outline the important role of TIL-B cells in anti-tumor immunity as 
suggested by many other studies. This approach may also lead to the identification of novel 



























Up to now the development of novel therapeutic or diagnostic antibodies for cancer is crucially 
restricted by the discovery of druggable targets especially in solid tumors, which in turn is 
complicated by the wide range of different cancer types, variable characteristics of the tumor 
cells and their microenvironment and the need of a tumor-selective expression.  
The present study describes the selection of cancer-cell-binding antibodies from the TIL-B 
antibody repertoire and the identification of the respective targets by immunoprecipitation and 
mass spectrometry to overcome the limitation to known tumor markers. Antibodies against 
well-described cancer-related proteins were isolated, demonstrating the great potential of this 
approach, which can be further improved in future investigations even for novel targets, target 
complexes and pathways. In this study, seven TIL-B libraries were constructed and analysed. 
Increasing the patient number for future experiments would diversify the considered antibody 
and target pools and greatly improve reliability of the NGS output, thus allowing a deeper 
insight into the V-gene usage and the clonality of TIL-Bs. Additionally, more cancer cell lines 
could be considered in the selection process to isolate antibodies against targets, which are 
shared on different cancer cells. This may increase the chance to discover universal cancer-
selective antibodies, which do not bind to normal cells. Considering, that in the present study 
nine out of 22 FaDu-binding antibodies were suitable for immunoprecipitation and further 
examined, several clones remained unidentified, which may deliver novel target proteins. 
Future investigations should focus on different strategies for target identification to overcome 
the limitation of immunoprecipitation, which usually requires high affinities. Analysis of peptide 
or protein arrays (Lawson et al. 2019) and the ORFeome phage display technology (Fühner et 
al. 2018) may contribute to successfully identify the targets of a broader range of antibodies. 
Regarding library construction, a differentiation of more defined B cell subpopulations may be 
beneficial to exclude bias caused by tumor-promoting Bregs or chemokine-attracted bystander 
B cells in future studies, for instance by implementing a more comprehensive immunostaining 
for flow cytometry. Fluorescence-activated cell sorting (FACS) would additionally allow 
construction of libraries based on single B cells in order to retain the natural antibody pairing 
(Tiller et al. 2008) further reducing potential bias within the libraries. Regarding the isolated 
antibodies against MMP-9, integrin-α3β1, CD9 and CD71, future experiments also need to 
include the identification of their individual epitopes and the characterisation of their effects on 
tumor cells by investigating their potential blocking, internalisation and cytotoxic abilities in 
cellular assays. Furthermore, tumor-selectivity should be analysed by immunohistochemistry 
to exclude cross-reactivity with non-tumoral tissue and to estimate if they may be applicable in 





Tumor-infiltrating lymphocytes (TIL) have been shown to contribute to an anti-tumor immunity 
correlating with improved survival of patients suffering from different types of cancer. Due to 
the close proximity to lymphatic tissue and the high frequency of related viral infections, 
cancers of the head and neck belong to the most highly infiltrated tumor types. Patients greatly 
benefit from immunotherapy, which aims to redirect or enhance their own anti-tumor immune 
response, but further development of efficient strategies is limited by the discovery of novel 
antibodies and targets. Tumor-infiltrating B cells (TIL-B) have been described as promising 
source of novel antigen-experienced and somatically hypermutated anti-tumor antibodies for 
many cancer types but published investigations considering head and neck cancers are rare.  
In the present study, novel antibodies against cancer-related proteins were isolated for the first 
time using the antibody repertoire of B cells infiltrating head and neck cancers. Human antibody 
gene libraries were constructed based on TIL-Bs isolated from fresh tumor specimens, 
analysed in next generation sequencing (NGS) and used for phage display selection. NGS 
analysis revealed an altered V-gene distribution within the TIL-B libraries compared to 
published naïve scFv-libraries and the in vivo repertoire. In some characteristics the TIL-B 
libraries were more similar to libraries, which were constructed from antigen-experienced B 
cells indicating a preferential V-gene usage in a disease context. Antibodies against the well-
known cancer target matrix metalloproteinase 9 (MMP-9) were isolated and characterised 
proving the presence of cancer-relevant antibodies within the TIL-B repertoire. To overcome 
the limitation to known antigens, TIL-B libraries were panned against the pharyngeal 
carcinoma cell line FaDu. Targets of the respective cell-binding antibodies were identified by 
immunoprecipitation and mass spectrometry revealing that nine of them bound to the cancer-
associated proteins integrin-α3β1, CD9 and CD71. Sequence analysis of the isolated anti-
integrin-α3β1 and anti-CD9 antibodies indicated clonal relation due to an identical V-gene 
recombination and frequent point mutations. The isolated antibodies were characterised and 
shown to be negligibly cross-reactive and affine to their respective target in various applications 
including ELISA, immunoprecipitation, flow cytometry and biolayer interferometry (BLI).  
In conclusion, this study describes the isolation of antibodies from TIL-B libraries against the 
well-known cancer-related targets MMP-9, integrin-α3β1, CD9 and CD71. The observed 
altered V-gene distribution within the libraries and the isolation of probably clonally related, 
highly mutated antibodies strongly indicate that they may have contributed to an anti-tumor 
immune response within the respective head and neck cancer patients. The identification of 
well-described cancer-related proteins as their targets demonstrates the vast potential of the 
TIL-B repertoire in the discovery of novel anti-tumor antibodies and may lead to the discovery 
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Suppl. Table 1: Overview of the NGS output considering read depth and unique sequences 
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